Trial Outcomes & Findings for Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy (NCT NCT00124982)

Last Updated: 2012-02-27

Results Overview

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with treatment.SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.Related AE/SAE=Certain,Probable,Possible,or Missing relationship to Drug

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

1286 participants

Primary outcome timeframe

Days 1-169

Results posted on

2012-02-27

Participant Flow

Of 1286 participants enrolled in this study, 240 were not treated.

Participant milestones

Participant milestones
Measure	Short Term (ST) Abatacept (ABA)-Previous User In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	Long-term ABA Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.
Short-term Period STARTED	449	597	0
Short-term Period COMPLETED	377	483	0
Short-term Period NOT COMPLETED	72	114	0
Long-term Period STARTED	0	0	530
Long-term Period COMPLETED	0	0	441
Long-term Period NOT COMPLETED	0	0	89

Reasons for withdrawal

Reasons for withdrawal
Measure	Short Term (ST) Abatacept (ABA)-Previous User In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	Long-term ABA Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.
Short-term Period Death	1	1	0
Short-term Period Adverse Event	17	22	0
Short-term Period Lack of Efficacy	32	73	0
Short-term Period Lost to Follow-up	8	5	0
Short-term Period Withdrawal of Consent	7	9	0
Short-term Period Poor/Non-compliance	3	1	0
Short-term Period No Longer Meets Study Criteria	1	2	0
Short-term Period Participant Decision	1	0	0
Short-term Period Participant Chose Own Doctor	0	1	0
Short-term Period Investigator Decision-No Specific AE	1	0	0
Short-term Period Participant Had Lymphopenia	1	0	0
Long-term Period Death	0	0	1
Long-term Period Adverse Event	0	0	17
Long-term Period Lack of Efficacy	0	0	46
Long-term Period Lost to Follow-up	0	0	4
Long-term Period Withdrawal by Subject	0	0	16
Long-term Period Pregnancy	0	0	1
Long-term Period Poor/Non-compliance	0	0	2
Long-term Period Administrative Reason by Sponsor	0	0	1
Long-term Period Neurologist Recommendation	0	0	1

Baseline Characteristics

Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	ST Abatacept (ABA)-Previous User n=449 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User n=597 Participants In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	Total n=1046 Participants Total of all reporting groups
Age Continuous	56.1 years STANDARD_DEVIATION 12.5 • n=5 Participants	53.2 years STANDARD_DEVIATION 12.3 • n=7 Participants	54.4 years STANDARD_DEVIATION 12.4 • n=5 Participants
Sex: Female, Male Female	359 Participants n=5 Participants	490 Participants n=7 Participants	849 Participants n=5 Participants
Sex: Female, Male Male	90 Participants n=5 Participants	107 Participants n=7 Participants	197 Participants n=5 Participants
Number of Tender Joints	17.8 tender joints STANDARD_DEVIATION 5.9 • n=5 Participants	17.8 tender joints STANDARD_DEVIATION 6.1 • n=7 Participants	17.8 tender joints STANDARD_DEVIATION 6.0 • n=5 Participants
Number of Swollen Joints	13.9 swollen joints STANDARD_DEVIATION 5.6 • n=5 Participants	13.5 swollen joints STANDARD_DEVIATION 5.4 • n=7 Participants	13.6 swollen joints STANDARD_DEVIATION 5.5 • n=5 Participants
Physical Function, Health Assessment Questionnaire Disability Index (HAQ-DI)	1.7 units on a scale STANDARD_DEVIATION 0.6 • n=5 Participants	1.7 units on a scale STANDARD_DEVIATION 0.6 • n=7 Participants	1.7 units on a scale STANDARD_DEVIATION 0.6 • n=5 Participants
hs-C-Reactive Protein (hs-CRP) Serum Levels	2.2 mg/dL STANDARD_DEVIATION 3.0 • n=5 Participants	2.1 mg/dL STANDARD_DEVIATION 3.0 • n=7 Participants	2.1 mg/dL STANDARD_DEVIATION 3.0 • n=5 Participants
Disease Activity Score (DAS) 28 (Using CRP Levels)	6.2 units on a scale STANDARD_DEVIATION 0.7 • n=5 Participants	6.2 units on a scale STANDARD_DEVIATION 0.7 • n=7 Participants	6.2 units on a scale STANDARD_DEVIATION 0.7 • n=5 Participants
Rheumatoid Factor (RF) Status Negative	138 participants n=5 Participants	215 participants n=7 Participants	353 participants n=5 Participants
Rheumatoid Factor (RF) Status Positive	292 participants n=5 Participants	349 participants n=7 Participants	641 participants n=5 Participants
Rheumatoid Factor (RF) Status Data Not Available	19 participants n=5 Participants	33 participants n=7 Participants	52 participants n=5 Participants

PRIMARY outcome

Timeframe: Days 1-169

Population: All treated participants

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=449 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User n=597 Participants In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations Death	1 participants	1 participants
Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations SAEs	50 participants	59 participants
Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations Related SAEs	10 participants	16 participants
Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations SAEs Leading to Discontinuation	9 participants	8 participants
Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations AEs	350 participants	473 participants
Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations Related AEs	190 participants	273 participants
Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations AEs Leading to Discontinuation	17 participants	24 participants

PRIMARY outcome

Timeframe: Days 1-169

Population: All treated participants

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=449 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User n=597 Participants In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Short-term Period: Number of Participants With AEs of Special Interest Infections (pre-specified)	26 participants	38 participants
Short-term Period: Number of Participants With AEs of Special Interest Serious Infections (pre-specified)	6 participants	7 participants
Short-term Period: Number of Participants With AEs of Special Interest Benign, malignant, and unspecified neoplasms	8 participants	7 participants
Short-term Period: Number of Participants With AEs of Special Interest Autoimmune disorders (pre-specified)	4 participants	9 participants
Short-term Period: Number of Participants With AEs of Special Interest Acute infusional AEs (pre-specified)	20 participants	37 participants
Short-term Period: Number of Participants With AEs of Special Interest Peri-infusional AEs (pre-specified)	57 participants	99 participants

PRIMARY outcome

Timeframe: Days 1-169

Population: Participants who received at least 1 infusion of abatacept during the short-term treatment period

Upper Normal Limit (ULN), Lower Normal Limit (LLN), Baseline (BL). Marked abnormality criteria are: Hemoglobin (HGB): \>3 g/dL decrease from BL; Hematocrit: \<0.75 \* BL; Erythrocytes: \<0.75 \* BL; Platelets (PLT): \<0.67 \* LLN/\>1.5 \* ULN, or if BL \< LLN then use 0.5 \* BL/\<100,000 mm\^3; Leukocytes: \<0.75 \* LLN/ \>1.25 \* ULN, or if BL\<LLN then use \<0.8 \* BL/\>ULN, or if BL\>ULN then use \>1.2 \* BL/\<LLN; neutrophils+bands: \<1.0 \* 10\^3 c/uL; eosinophils: \>0.750 \* 10\^3 c/uL; basophils: \> 400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750 \* 10\^3 c/uL/ \>7.50 \* 10\^3 c/uL.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=429 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User n=581 Participants In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Short-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria Low HGB (n=429, n=581)	2 participants	3 participants
Short-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria Low hematocrit (n=428, n=580)	1 participants	2 participants
Short-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria Low erythrocytes (n=429, n=581)	1 participants	2 participants
Short-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria Low PLT (n=424, n=578)	1 participants	1 participants
Short-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria High PLT (n=424, n=578)	0 participants	0 participants
Short-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria Low leukocytes (n=429, n=581)	2 participants	1 participants
Short-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria High leukocytes (n=429, n=581)	3 participants	8 participants
Short-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria Low neutrophils+bands (n=429, n=580)	0 participants	1 participants
Short-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria High eosinophils (n=429, n=580)	2 participants	2 participants
Short-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria High basophils (n=429, n=580)	0 participants	0 participants
Short-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria High monocytes (n=429, n=580)	1 participants	0 participants
Short-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria Low lymphocytes (n=429, n=580)	30 participants	27 participants
Short-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria High lymphocytes (n=429, n=580)	0 participants	0 participants

PRIMARY outcome

Timeframe: Days 1-169

Population: All treated participants. n=number of participants with evaluable laboratory results.

Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\* ULN, or if BL\>ULN then use \>3\* BL; aspartate aminotransferase (AST): \>3\* ULN, or if BL\>ULN then use \>4\* BL; alanine aminotransferase (ALT): \>3\* ULN, or if BL\>ULN then use \>4\* BL; G-Glutamyl transferase (GGT): \>2\* ULN, or if BL\>ULN then use \>3\* BL; Bilirubin: \>2\* ULN, or if BL\>ULN then use \>4\* BL; blood urea nitrogen (BUN): \>2\* BL; creatinine: \>1.5\* BL

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=428 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User n=583 Participants In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Short-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA Criteria High ALP (n=428, n=583)	0 participants	0 participants
Short-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA Criteria High AST (n=426, n=583)	1 participants	2 participants
Short-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA Criteria High ALT (n=426, n=583)	2 participants	1 participants
Short-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA Criteria High GGT (n=427, n=583)	1 participants	5 participants
Short-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA Criteria High bilirubin (n=426, n=583)	1 participants	1 participants
Short-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA Criteria High BUN (n=428, n=583)	3 participants	8 participants
Short-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA Criteria High creatinine (n=427, n=583)	8 participants	7 participants

PRIMARY outcome

Timeframe: Days 1-169

Population: All treated participants. n=number of participants with evaluable laboratory results.

Marked abnormality criteria:Sodium (Na): \<0.95\* LLN/ \>1.05\* ULN,or if BL\<LLN then use 0.95\* BL or \>ULN,or if BL\>ULN then use\>1.05\* BL or \<LLN; potassium (K): \<0.9\* LLN/\>1.1\* ULN,or if BL\<LLN then use 0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; chloride: \<0.9\* LLN/\>1.1\* ULN, or if BL\<LLN then use 0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; calcium (Ca): \<0.8\* LLN/\>1.2\* ULN, or if BL\<LLN then use 0.75\* BL or \>ULN, or if BL\>ULN then use\>1.25\* BL or \<LLN; phosphorous (P): \<0.75\* LLN/ \>1.25\* ULN, or if BL\<LLN then use 0.67\* BL or \>ULN, or if BL\>ULN then use\>1.33\* BL or \<LLN

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=428 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User n=583 Participants In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Short-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria Low Na (n=428, n=583)	0 participants	2 participants
Short-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria High Na (n=428, n=583)	0 participants	0 participants
Short-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria Low K (n=425, n=583)	1 participants	3 participants
Short-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria High K (n=425, n=583)	0 participants	0 participants
Short-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria Low chloride (n=428, n=583)	0 participants	0 participants
Short-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria High chloride (n=428, n=583)	0 participants	0 participants
Short-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria Low Ca (n=428, n=583)	2 participants	0 participants
Short-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria High Ca (n=428, n=583)	0 participants	0 participants
Short-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria Low P (n=426, n=583)	1 participants	0 participants
Short-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria High P (n=426, n=583)	3 participants	1 participants

PRIMARY outcome

Timeframe: Days 1-169

Population: All treated participants. n=number of participants with evaluable laboratory results.

Marked abnormality criteria: serum glucose (Glu):\<65 mg/dL/ \>220 mg/dL; fasting serum Glu: \<0.8\* LLN/\>1.5\* ULN, or if BL\<LLN then use 0.8\* BL or \>ULN, or if BL\>ULN then use \>2.0\* BL or \<LLN; total protein: \<0.9\* LLN/\>1.1\* ULN; albumin: \<0.9\* LLN,or if BL\<LLN then use \<0.75 BL; uric acid: \>1.5\* ULN, or if BL\>ULN then use \>2\* BL. Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]):Use ≥2 when BL value missing or value ≥4,or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=428 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User n=583 Participants In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Short-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria Low Glu (n=427, n=583)	7 participants	17 participants
Short-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria High Glu (n=427, n=583)	12 participants	21 participants
Short-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria Low protein (n=428, n=583)	0 participants	0 participants
Short-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria High protein (n=428, n=583)	0 participants	0 participants
Short-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria Low albumin (n=428, n=583)	1 participants	2 participants
Short-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria High uric acid (n=428, n=583)	0 participants	0 participants
Short-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria High urine protein (n=298, n=421)	4 participants	2 participants
Short-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria High urine glucose (n=298, n=421)	0 participants	4 participants
Short-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria High urine blood (n=298, n=421)	5 participants	14 participants
Short-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria High urine leukocyte esterase (n=297, n=491)	20 participants	17 participants
Short-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria High urine RBC (n=68, n=98)	13 participants	17 participants
Short-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria High urine WBC (n=80, n=117)	30 participants	36 participants

PRIMARY outcome

Timeframe: Day 1 (Baseline) -Day 169

Population: Although mean values for systolic and diastolic blood pressure were recorded, mean changes from baseline were not summarized for these data.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Days 1-169

Population: Treated participants with available serum samples for assay

Serum samples from all treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=41 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Short-term Period: Number of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Responses by Enzyme-Linked Immunosorbant Assay (ELISA) Anti-CTLA4 antibodies	0 participants	—
Short-term Period: Number of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Responses by Enzyme-Linked Immunosorbant Assay (ELISA) Anti-abatacept antibodies	12 participants	—

PRIMARY outcome

Timeframe: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept

Population: All treated participants

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=530 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations Death	1 participants	—
Long-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations SAEs	61 participants	—
Long-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations Related SAEs	15 participants	—
Long-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations SAEs Leading to Discontinuation	11 participants	—
Long-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations AEs	328 participants	—
Long-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations Related AEs	146 participants	—
Long-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations AEs Leading to Discontinuation	15 participants	—

PRIMARY outcome

Timeframe: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept

Population: All treated participants

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=530 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Number of Participants With AEs of Special Interest Infections (pre-specified)	177 participants	—
Long-term Period: Number of Participants With AEs of Special Interest Malignant neoplasms	4 participants	—
Long-term Period: Number of Participants With AEs of Special Interest Autoimmune disorders (pre-specified)	8 participants	—
Long-term Period: Number of Participants With AEs of Special Interest Peri-infusional AEs (pre-specified)	42 participants	—
Long-term Period: Number of Participants With AEs of Special Interest Acute infusional AEs (pre-specified)	14 participants	—

PRIMARY outcome

Timeframe: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept

Population: Participants who received at least 1 infusion of abatacept during the long-term treatment period. n=number of participants with evaluable laboratory results.

ULN=upper limit of normal; LLN=lower limit of normal; BL=baseline. Marked abnormality criteria=Hemoglobin: \>3 g/dL decrease from BL; Hematocrit: \<0.75\*BL; Erythrocytes:\<0.75\*BL; Platelets: \<0.67\*LLN/\>1.5 \* ULN, or if BL\<LLN, use 0.5\*BL/\<100,000 mm\^3; Leukocytes: \<0.75\*LLN/\>1.25\*ULN, or if BL\<LLN, use \<0.8\*BL/\>ULN, or if BL\>ULN,use \>1.2\*BL/\<LLN; neutrophils+bands: \<1.0\*10\^3 c/uL; eosinophils: \>0.750\*10\^3 c/uL; basophils: \>400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750\*10\^3 c/uL/\>7.50\*10\^3 c/uL.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=513 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria Low hemoglobin (n=513)	1 participants	—
Long-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria Low hematocrit (n=510)	1 participants	—
Long-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria Low erythrocytes (n=513)	1 participants	—
Long-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria Low platelets (n=500)	0 participants	—
Long-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria High platelets (n=500)	1 participants	—
Long-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria Low leukocytes (n=513)	1 participants	—
Long-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria High leukocytes (n=513)	8 participants	—
Long-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria Low neutrophils+bands (510)	0 participants	—
Long-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria Low lymphocytes (n=510)	34 participants	—
Long-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria High lymphocytes (n=510)	0 participants	—
Long-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria High monocytes (n=510)	2 participants	—
Long-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria High basophils (n=510)	1 participants	—
Long-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria High eosinophils (n=510)	13 participants	—

PRIMARY outcome

Timeframe: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept

Population: All treated participants. n=number of participants with evaluable laboratory results.

Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\*ULN, or if BL\>ULN, use \>3\*BL; aspartate aminotransferase (AST): \>3\*ULN, or if BL\>ULN,use \>4\*BL; alanine aminotransferase (ALT): \>3\*ULN, or if BL\>ULN, use \>4\*BL; G-Glutamyl transferase (GGT): \>2\*ULN, or if BL\>ULN, use \>3\*BL; bilirubin: \>2\*ULN, or if BL\>ULN, use \>4\*BL; blood urea nitrogen (BUN): \>2\*BL; creatinine: \>1.5\*BL

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=514 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA Criteria High ALT (n=512)	5 participants	—
Long-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA Criteria High ALP (n=514)	0 participants	—
Long-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA Criteria High AST (n=512)	1 participants	—
Long-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA Criteria High GGT (n=512)	10 participants	—
Long-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA Criteria High bilirubin (n=513)	1 participants	—
Long-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA Criteria High BUN (n=513)	5 participants	—
Long-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA Criteria High creatinine (n=512)	8 participants	—

PRIMARY outcome

Timeframe: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept

Population: All treated participants. n=number of participants with evaluable laboratory results.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=513 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria Low Na (n=513)	1 participants	—
Long-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria High Na (n=513)	3 participants	—
Long-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria Low K (n=510)	4 participants	—
Long-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria High K (n=510)	1 participants	—
Long-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria Low chloride (n=513)	1 participants	—
Long-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria High chloride (n=513)	1 participants	—
Long-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria Low Ca (n=513)	0 participants	—
Long-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria High Ca (n=513)	1 participants	—
Long-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria Low P (n=512)	0 participants	—
Long-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria High P (n=512)	3 participants	—

PRIMARY outcome

Timeframe: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept

Population: All treated participants. n=number of participants with evaluable laboratory results.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=513 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria Low glu (n=513)	15 participants	—
Long-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria High glu (n=513)	17 participants	—
Long-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria Low protein (n=513)	1 participants	—
Long-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria High protein (n=513)	0 participants	—
Long-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria Low albumin (n=511)	1 participants	—
Long-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria High uric acid (n=513)	0 participants	—
Long-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria High urine protein (n=462)	4 participants	—
Long-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria High urine glucose (n=462)	5 participants	—
Long-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria High urine blood (n=462)	10 participants	—
Long-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria High urine leukocyte esterase (n=462)	13 participants	—
Long-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria High urine RBC (n=91)	24 participants	—
Long-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria High urine WBC (n=91)	11 participants	—

PRIMARY outcome

Timeframe: BL, Day 365, Day 729

Population: All treated participants in the OL. n=number of participants with evaluable laboratory results.

HGB normal range (NR)=11.6 - 16.2 g/dL, marked abnormality (MA) is \>3 g/dL decrease from BL. Total protein NR=6.0 - 8.4 g/dL, MA is \<0.9\* LLN/\>1.1\* ULN; Albumin NR=3.5 - 5.3 g/dL, MA is \<0.9\* LLN, or if BL\<LLN then use \<0.75 BL

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=218 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Change From Baseline in Hemoglobin (HGB), Total Protein, and Albumin Over Time Day 365 HGB (n=218)	0.40 g/dL Standard Deviation 0.08	—
Long-term Period: Change From Baseline in Hemoglobin (HGB), Total Protein, and Albumin Over Time Day 365 total protein (n=217)	-0.22 g/dL Standard Deviation 0.04	—
Long-term Period: Change From Baseline in Hemoglobin (HGB), Total Protein, and Albumin Over Time Day 365 albumin (n=217)	0.13 g/dL Standard Deviation 0.02	—
Long-term Period: Change From Baseline in Hemoglobin (HGB), Total Protein, and Albumin Over Time Day 729 HGB (n=62)	0.47 g/dL Standard Deviation 0.18	—
Long-term Period: Change From Baseline in Hemoglobin (HGB), Total Protein, and Albumin Over Time Day 729 total protein (n=65)	-0.59 g/dL Standard Deviation 0.07	—
Long-term Period: Change From Baseline in Hemoglobin (HGB), Total Protein, and Albumin Over Time Day 729 albumin (n=65)	0.16 g/dL Standard Deviation 0.04	—

PRIMARY outcome

Timeframe: BL, Day 365, Day 729

Population: All treated participants in the OL. n=number of participants with evaluable laboratory results.

The hematocrit value refers to the percentage of blood volume that is occupied by red blood cells. Hematocrit values for participants were expressed as percentages and were averaged to yield a group mean value (percentage) at a particular time point. The mean change from baseline in hematocrit value (expressed as a percent)= mean post-baseline value (expressed as a percent) - mean baseline value (expressed as a percent).

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=213 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Change From Baseline in Hematocrit Over Time Day 365 hematocrit (n=213)	1.00 percentage change Standard Deviation 0.22	—
Long-term Period: Change From Baseline in Hematocrit Over Time Day 729 HGB (n=61)	0.81 percentage change Standard Deviation 0.47	—

PRIMARY outcome

Timeframe: BL, Day 365, Day 729

Population: All treated participants in the OL. n=number of participants with evaluable laboratory results.

Erythrocytes NR= 3.80 - 5.50 \*10\^6 c/uL, MA is \<0.75 \* BL

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=218 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Change From Baseline in Erythrocytes Over Time Day 365 erythrocytes (n=218)	0.04 10^6 c/uL Standard Deviation 0.02	—
Long-term Period: Change From Baseline in Erythrocytes Over Time Day 729 erythrocytes (n=62)	0.06 10^6 c/uL Standard Deviation 0.04	—

PRIMARY outcome

Timeframe: BL, Day 365, Day 729

Population: All treated participants in the OL. n=number of participants with evaluable laboratory results.

Erythrocytes NR= 3.80 - 5.50 \*10\^6 c/uL, MA is \<0.75 \* BL

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=214 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Change From Baseline in Platelets (PLT) Over Time Day 365 PLT (n=214)	-41.2 10^9 c/L Standard Deviation 6.24	—
Long-term Period: Change From Baseline in Platelets (PLT) Over Time Day 729 PLT (n=61)	-67.7 10^9 c/L Standard Deviation 11.02	—

PRIMARY outcome

Timeframe: BL, Day 365, Day 729

Population: All treated participants in the OL. n=number of participants with evaluable laboratory results.

Leukocytes NR=4.1 - 12.3\*10\^3 c/uL, MA is \<0.75 \* LLN/ \>1.25 \* ULN, or if BL\<LLN then use \<0.8 \* BL/\>ULN, or if BL\>ULN then use \>1.2 \* BL/\<LLN. Neutrophils+bands MA is \<1.0 \* 10\^3 c/uL. Eosinophils MA is \>0.750 \* 10\^3 c/uL. Basophils MA is \> 400 mm\^3. Monocytes MA is \>2000 mm\^3. Lymphocytes MA is \<0.750 \* 10\^3 c/uL/ \>7.50 \* 10\^3 c/uL

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=218 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Change From Baseline in White Blood Cells Over Time Day 729 basophils (n=62)	0.00 10^3 c/uL Standard Deviation 0.00	—
Long-term Period: Change From Baseline in White Blood Cells Over Time Day 365 leukocytes (n=218)	-0.86 10^3 c/uL Standard Deviation 0.17	—
Long-term Period: Change From Baseline in White Blood Cells Over Time Day 365 neutrophils (n=215)	-0.83 10^3 c/uL Standard Deviation 0.16	—
Long-term Period: Change From Baseline in White Blood Cells Over Time Day 365 eosinophils (n=215)	-0.01 10^3 c/uL Standard Deviation 0.01	—
Long-term Period: Change From Baseline in White Blood Cells Over Time Day 365 monocytes (n=215)	0.00 10^3 c/uL Standard Deviation 0.02	—
Long-term Period: Change From Baseline in White Blood Cells Over Time Day 365 basophils (n=215)	0.00 10^3 c/uL Standard Deviation 0.00	—
Long-term Period: Change From Baseline in White Blood Cells Over Time Day 365 lymphocytes (n=215)	0.08 10^3 c/uL Standard Deviation 0.05	—
Long-term Period: Change From Baseline in White Blood Cells Over Time Day 729 leukocytes (n=62)	-1.49 10^3 c/uL Standard Deviation 0.26	—
Long-term Period: Change From Baseline in White Blood Cells Over Time Day 729 neutrophils (n=62)	-1.56 10^3 c/uL Standard Deviation 0.27	—
Long-term Period: Change From Baseline in White Blood Cells Over Time Day 729 eosinophils (n=62)	-0.02 10^3 c/uL Standard Deviation 0.02	—
Long-term Period: Change From Baseline in White Blood Cells Over Time Day 729 monocytes (n=62)	-0.01 10^3 c/uL Standard Deviation 0.03	—
Long-term Period: Change From Baseline in White Blood Cells Over Time Day 729 lymphocytes (n=62)	0.10 10^3 c/uL Standard Deviation 0.09	—

PRIMARY outcome

Timeframe: BL, Day 365, Day 729

Population: All treated participants in the OL. n=number of participants with evaluable laboratory results.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=218 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and G-Glutamyl Transferase (GGT) Over Time Day 365 ALP (n=218)	0.81 U/L Standard Deviation 2.64	—
Long-term Period: Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and G-Glutamyl Transferase (GGT) Over Time Day 365 AST (n=212)	0.64 U/L Standard Deviation 1.09	—
Long-term Period: Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and G-Glutamyl Transferase (GGT) Over Time Day 365 ALT (n=212)	0.76 U/L Standard Deviation 1.80	—
Long-term Period: Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and G-Glutamyl Transferase (GGT) Over Time Day 365 GGT (n=217)	2.21 U/L Standard Deviation 3.61	—
Long-term Period: Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and G-Glutamyl Transferase (GGT) Over Time Day 729 ALP (n=64)	-8.44 U/L Standard Deviation 5.82	—
Long-term Period: Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and G-Glutamyl Transferase (GGT) Over Time Day 729 AST (n=63)	1.35 U/L Standard Deviation 2.38	—
Long-term Period: Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and G-Glutamyl Transferase (GGT) Over Time Day 729 ALT (n=63)	2.60 U/L Standard Deviation 3.92	—
Long-term Period: Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and G-Glutamyl Transferase (GGT) Over Time Day 729 GGT (n=64)	0.13 U/L Standard Deviation 2.34	—

PRIMARY outcome

Timeframe: BL, Day 365, Day 729

Population: All treated participants in the OL. n=number of participants with evaluable laboratory results.

Bilirubin NR=0.2-1.2 mg/dL, MA: \>2\* ULN, or if BL\>ULN then use \>4\* BL. BUN NR=4.0-24.0 mg/dL, MA: \>2\*BL. Creatinine NR=0.4-1.2 mg/dL, MA: \>1.5\*BL. Ca NR=8.8-10.2 mg/dL, MA: \<0.8\*LLN/\>1.2\*ULN, or if BL\<LLN then use 0.75\*BL or \>ULN, or if BL\>ULN then use\>1.25\*BL or \<LLN. P NR=2.8-4.0 mg/dL, MA: \<0.75\*LLN/ \>1.25\*ULN, or if BL\<LLN then use 0.67\*BL or \>ULN, or if BL\>ULN then use\>1.33\*BL or \<LLN. Glu MA: \<65 mg/dL/ \>220 mg/dL. Uric acid MA: \>1.5\*ULN, or if BL\>ULN then use \>2\*BL.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=217 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Change From Baseline in Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, Calcium (Ca), Phosphorus (P), Serum Glucose (Glu), and Uric Acid Over Time Day 365 bilirubin (n=210)	0.04 mg/dL Standard Deviation 0.01	—
Long-term Period: Change From Baseline in Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, Calcium (Ca), Phosphorus (P), Serum Glucose (Glu), and Uric Acid Over Time Day 365 BUN (n=217)	0.85 mg/dL Standard Deviation 0.31	—
Long-term Period: Change From Baseline in Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, Calcium (Ca), Phosphorus (P), Serum Glucose (Glu), and Uric Acid Over Time Day 365 creatinine (n=217)	0.05 mg/dL Standard Deviation 0.01	—
Long-term Period: Change From Baseline in Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, Calcium (Ca), Phosphorus (P), Serum Glucose (Glu), and Uric Acid Over Time Day 365 Ca (n=217)	0.11 mg/dL Standard Deviation 0.03	—
Long-term Period: Change From Baseline in Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, Calcium (Ca), Phosphorus (P), Serum Glucose (Glu), and Uric Acid Over Time Day 365 P (n=217)	0.13 mg/dL Standard Deviation 0.04	—
Long-term Period: Change From Baseline in Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, Calcium (Ca), Phosphorus (P), Serum Glucose (Glu), and Uric Acid Over Time Day 365 Glu (n=217)	0.83 mg/dL Standard Deviation 2.26	—
Long-term Period: Change From Baseline in Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, Calcium (Ca), Phosphorus (P), Serum Glucose (Glu), and Uric Acid Over Time Day 365 uric acid (n=217)	-0.18 mg/dL Standard Deviation 0.07	—
Long-term Period: Change From Baseline in Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, Calcium (Ca), Phosphorus (P), Serum Glucose (Glu), and Uric Acid Over Time Day 729 bilirubin (n=65)	-0.01 mg/dL Standard Deviation 0.02	—
Long-term Period: Change From Baseline in Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, Calcium (Ca), Phosphorus (P), Serum Glucose (Glu), and Uric Acid Over Time Day 729 BUN (n=65)	0.77 mg/dL Standard Deviation 0.54	—
Long-term Period: Change From Baseline in Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, Calcium (Ca), Phosphorus (P), Serum Glucose (Glu), and Uric Acid Over Time Day 729 creatinine (n=65)	0.04 mg/dL Standard Deviation 0.02	—
Long-term Period: Change From Baseline in Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, Calcium (Ca), Phosphorus (P), Serum Glucose (Glu), and Uric Acid Over Time Day 729 Ca (n=65)	0.07 mg/dL Standard Deviation 0.06	—
Long-term Period: Change From Baseline in Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, Calcium (Ca), Phosphorus (P), Serum Glucose (Glu), and Uric Acid Over Time Day 729 P (n=64)	-0.77 mg/dL Standard Deviation 0.08	—
Long-term Period: Change From Baseline in Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, Calcium (Ca), Phosphorus (P), Serum Glucose (Glu), and Uric Acid Over Time Day 729 Glu (n=64)	1.71 mg/dL Standard Deviation 2.94	—
Long-term Period: Change From Baseline in Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, Calcium (Ca), Phosphorus (P), Serum Glucose (Glu), and Uric Acid Over Time Day 729 uric acid (n=65)	0.11 mg/dL Standard Deviation 0.11	—

PRIMARY outcome

Timeframe: BL, Day 365, Day 729

Population: All treated participants in the OL. n=number of participants with evaluable laboratory results.

Na NR=132 - 147 mEq/L, MA is 95\* LLN/ \>1.05\* ULN, or if BL\<LLN then use 0.95\* BL or \>ULN, or if BL\>ULN then use\>1.05\* BL or \<LLN. K NR=3.3 - 5.5 mEq/L, MA is \<0.9\* LLN/\>1.1\* ULN,or if BL\<LLN then use 0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN. Cl NR=94 - 111 mEq/L, MA is \<0.9\* LLN/\>1.1\* ULN, or if BL\<LLN then use 0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=217 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
LT; Change From Baseline in Sodium (Na), Potassium (K), Chloride (Cl) Over Time Day 365 Na (n=216)	-0.91 mEq/L Standard Deviation 0.25	—
LT; Change From Baseline in Sodium (Na), Potassium (K), Chloride (Cl) Over Time Day 365 K (n=210)	-0.08 mEq/L Standard Deviation 0.03	—
LT; Change From Baseline in Sodium (Na), Potassium (K), Chloride (Cl) Over Time Day 365 Cl (n=217)	-0.37 mEq/L Standard Deviation 0.25	—
LT; Change From Baseline in Sodium (Na), Potassium (K), Chloride (Cl) Over Time Day 729 Na (n=65)	1.23 mEq/L Standard Deviation 0.33	—
LT; Change From Baseline in Sodium (Na), Potassium (K), Chloride (Cl) Over Time Day 729 K (n=63)	-0.06 mEq/L Standard Deviation 0.06	—
LT; Change From Baseline in Sodium (Na), Potassium (K), Chloride (Cl) Over Time Day 729 Cl (n=65)	1.42 mEq/L Standard Deviation 0.37	—

PRIMARY outcome

Timeframe: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept

Population: All treated participants. n=number of participants with evaluable blood pressure measurements.

Measurements were taken in a seated position before and after abatacept infusion.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=482 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 169 SBP pre-infusion (n=482)	125.1 mm Hg Standard Deviation 16.02	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 169 SBP post-infusion (n=478)	125.3 mm Hg Standard Deviation 16.03	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 197 SBP pre-infusion (n=414)	124.4 mm Hg Standard Deviation 16.98	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 197 SBP post-infusion (n=415)	123.9 mm Hg Standard Deviation 16.84	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 225 SBP pre-infusion (n=340)	123.9 mm Hg Standard Deviation 16.33	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 225 SBP post-infusion (n=338)	123.4 mm Hg Standard Deviation 16.59	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 253 SBP pre-infusion (n=251)	124.0 mm Hg Standard Deviation 17.47	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 253 SBP post-infusion (n=251)	124.9 mm Hg Standard Deviation 16.57	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 281 SBP pre-infusion (n=203)	124.2 mm Hg Standard Deviation 17.25	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 281 SBP post-infusion (n=202)	124.8 mm Hg Standard Deviation 16.62	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 309 SBP pre-infusion (n=160)	124.1 mm Hg Standard Deviation 18.09	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 309 SBP post-infusion (n=159)	123.8 mm Hg Standard Deviation 17.58	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 337 SBP pre-infusion (n=128)	124.8 mm Hg Standard Deviation 16.84	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 337 SBP post-infusion (n=128)	124.0 mm Hg Standard Deviation 18.84	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 365 SBP pre-infusion (n=118)	126.2 mm Hg Standard Deviation 17.47	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 365 SBP post-infusion (n=120)	125.0 mm Hg Standard Deviation 15.85	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 393 SBP pre-infusion (n=101)	123.0 mm Hg Standard Deviation 18.74	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 393 SBP post-infusion (n=99)	124.1 mm Hg Standard Deviation 17.06	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 421 SBP post-infusion (n=93)	124.4 mm Hg Standard Deviation 15.84	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 449 SBP pre-infusion (n=82)	125.8 mm Hg Standard Deviation 18.29	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 449 SBP post-infusion (n=82)	124.0 mm Hg Standard Deviation 17.25	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 477 SBP pre-infusion (n=75)	125.3 mm Hg Standard Deviation 19.03	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 477 SBP post-infusion (n=75)	122.9 mm Hg Standard Deviation 16.36	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 505 SBP pre-infusion (n=72)	124.3 mm Hg Standard Deviation 20.88	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 505 SBP post-infusion (n=73)	122.7 mm Hg Standard Deviation 17.08	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 533 SBP pre-infusion (n=67)	125.4 mm Hg Standard Deviation 16.73	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 533 SBP post-infusion (n=66)	125.2 mm Hg Standard Deviation 17.57	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 561 SBP pre-infusion (n=63)	121.6 mm Hg Standard Deviation 18.36	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 561 SBP post-infusion (n=63)	120.6 mm Hg Standard Deviation 18.94	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 589 SBP pre-infusion (n=57)	119.6 mm Hg Standard Deviation 15.98	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 589 SBP post-infusion (n=57)	121.1 mm Hg Standard Deviation 18.49	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 617 SBP pre-infusion (n=56)	122.1 mm Hg Standard Deviation 15.62	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 617 SBP post-infusion (n=56)	122.3 mm Hg Standard Deviation 18.57	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 645 SBP pre-infusion (n=44)	120.0 mm Hg Standard Deviation 18.78	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 645 SBP post-infusion (n=43)	121.8 mm Hg Standard Deviation 18.33	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 673 SBP pre-infusion (n=40)	123.4 mm Hg Standard Deviation 18.53	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 673 SBP post-infusion (n=41)	123.6 mm Hg Standard Deviation 17.90	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 701 SBP pre-infusion (n=35)	119.4 mm Hg Standard Deviation 16.82	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 701 SBP post-infusion (n=36)	117.6 mm Hg Standard Deviation 15.57	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 729 SBP pre-infusion (n=32)	121.5 mm Hg Standard Deviation 21.43	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 729 SBP post-infusion (n=32)	121.9 mm Hg Standard Deviation 17.48	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 757 SBP pre-infusion (n=30)	121.1 mm Hg Standard Deviation 16.36	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 757 SBP post-infusion (n=29)	118.3 mm Hg Standard Deviation 19.11	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 785 SBP pre-infusion (n=25)	119.1 mm Hg Standard Deviation 19.97	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 785 SBP post-infusion (n=25)	117.3 mm Hg Standard Deviation 18.64	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 813 SBP pre-infusion (n=23)	118.4 mm Hg Standard Deviation 12.24	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 813 SBP post-infusion (n=22)	123.0 mm Hg Standard Deviation 14.08	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 841 SBP pre-infusion (n=19)	115.3 mm Hg Standard Deviation 15.92	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 841 SBP post-infusion (n=19)	119.1 mm Hg Standard Deviation 18.52	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 869 SBP pre-infusion (n=18)	117.6 mm Hg Standard Deviation 14.84	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 869 SBP post-infusion (n=18)	117.6 mm Hg Standard Deviation 14.22	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 897 SBP pre-infusion (n=19)	116.4 mm Hg Standard Deviation 14.18	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 897 SBP post-infusion (n=19)	115.4 mm Hg Standard Deviation 12.81	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 925 SBP pre-infusion (n=19)	116.4 mm Hg Standard Deviation 16.33	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 925 SBP post-infusion (n=19)	118.2 mm Hg Standard Deviation 18.78	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 953 SBP pre-infusion (n=19)	116.8 mm Hg Standard Deviation 15.97	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 953 SBP post-infusion (n=19)	119.5 mm Hg Standard Deviation 20.01	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 981 SBP pre-infusion (n=18)	115.6 mm Hg Standard Deviation 16.18	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 981 SBP post-infusion (n=18)	118.4 mm Hg Standard Deviation 18.75	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 1009 SBP pre-infusion (n=19)	116.8 mm Hg Standard Deviation 20.57	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 1009 SBP post-infusion (n=19)	118.9 mm Hg Standard Deviation 13.70	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 1037 SBP pre-infusion (n=15)	113.5 mm Hg Standard Deviation 16.51	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 1037 SBP post-infusion (n=15)	115.3 mm Hg Standard Deviation 15.39	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 1065 SBP pre-infusion (n=14)	123.1 mm Hg Standard Deviation 24.47	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 1065 SBP post-infusion (n=14)	119.4 mm Hg Standard Deviation 16.84	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 1093 SBP pre-infusion (n=10)	116.5 mm Hg Standard Deviation 18.31	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 1093 SBP post-infusion (n=10)	113.5 mm Hg Standard Deviation 14.54	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 1121 SBP pre-infusion (n=7)	118.3 mm Hg Standard Deviation 20.93	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 1121 SBP post-infusion (n=7)	115.1 mm Hg Standard Deviation 11.87	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 1149 SBP pre-infusion (n=7)	116.9 mm Hg Standard Deviation 13.91	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 1149 SBP post-infusion (n=7)	116.4 mm Hg Standard Deviation 8.98	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 1177 SBP pre-infusion (n=7)	114.6 mm Hg Standard Deviation 12.43	—
Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time Day 1177 SBP post-infusion (n=7)	114.6 mm Hg Standard Deviation 7.72	—

PRIMARY outcome

Timeframe: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept

Population: All treated participants. n=number of participants with evaluable blood pressure readings.

Measurements were taken in a seated position before and after abatacept infusion.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=481 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 673 DBP post-infusion (n=41)	75.1 mm Hg Standard Deviation 10.41	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 701 DBP pre-infusion (n=35)	72.0 mm Hg Standard Deviation 9.39	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 701 DBP post-infusion (n=36)	72.3 mm Hg Standard Deviation 8.70	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 729 DBP pre-infusion (n=32)	76.7 mm Hg Standard Deviation 11.66	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 729 DBP post-infusion (n=32)	74.8 mm Hg Standard Deviation 10.34	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 757 DBP pre-infusion (n=30)	75.0 mm Hg Standard Deviation 9.34	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 757 DBP post-infusion (n=29)	73.8 mm Hg Standard Deviation 10.07	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 785 DBP pre-infusion (n=24)	73.5 mm Hg Standard Deviation 10.46	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 785 DBP post-infusion (n=25)	72.7 mm Hg Standard Deviation 9.32	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 813 DBP pre-infusion (n=22)	75.2 mm Hg Standard Deviation 8.05	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 813 DBP post-infusion (n=22)	73.9 mm Hg Standard Deviation 10.95	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 841 DBP pre-infusion (n=19)	72.4 mm Hg Standard Deviation 8.41	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 841 DBP post-infusion (n=19)	73.2 mm Hg Standard Deviation 10.87	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 869 DBP pre-infusion (n=19)	72.7 mm Hg Standard Deviation 10.61	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 869 DBP post-infusion (n=18)	71.1 mm Hg Standard Deviation 9.86	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 897 DBP pre-infusion (n=19)	68.8 mm Hg Standard Deviation 7.44	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 897 DBP post-infusion (n=19)	67.9 mm Hg Standard Deviation 7.69	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 925 DBP pre-infusion (n=19)	73.5 mm Hg Standard Deviation 9.96	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 925 DBP post-infusion (n=19)	71.8 mm Hg Standard Deviation 10.77	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 953 DBP pre-infusion (n=19)	68.7 mm Hg Standard Deviation 10.91	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 953 DBP post-infusion (n=19)	72.5 mm Hg Standard Deviation 10.74	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 981 DBP pre-infusion (n=18)	69.7 mm Hg Standard Deviation 11.05	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 981 DBP post-infusion (n=18)	69.7 mm Hg Standard Deviation 11.45	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 1009 DBP pre-infusion (n=19)	71.6 mm Hg Standard Deviation 9.78	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 1009 DBP post-infusion (n=19)	70.3 mm Hg Standard Deviation 9.16	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 1037 DBP pre-infusion (n=15)	71.3 mm Hg Standard Deviation 11.15	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 1037 DBP post-infusion (n=15)	71.2 mm Hg Standard Deviation 8.48	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 1065 DBP pre-infusion (n=13)	71.5 mm Hg Standard Deviation 7.18	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 1065 DBP post-infusion (n=14)	72.4 mm Hg Standard Deviation 7.53	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 1093 DBP pre-infusion (n=10)	71.8 mm Hg Standard Deviation 6.07	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 1093 DBP post-infusion (n=10)	76.3 mm Hg Standard Deviation 5.58	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 1121 DBP pre-infusion (n=7)	75.1 mm Hg Standard Deviation 5.64	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 1121 DBP post-infusion (n=7)	72.6 mm Hg Standard Deviation 4.08	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 1149 DBP pre-infusion (n=7)	72.6 mm Hg Standard Deviation 4.16	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 1149 DBP post-infusion (n=7)	72.4 mm Hg Standard Deviation 3.99	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 1177 DBP pre-infusion (n=7)	69.1 mm Hg Standard Deviation 9.32	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 1177 DBP post-infusion (n=7)	73.4 mm Hg Standard Deviation 7.35	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 169 DBP pre-infusion (n=481)	75.1 mm Hg Standard Deviation 10.09	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 169 DBP post-infusion (n=477)	74.9 mm Hg Standard Deviation 9.60	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 197 DBP pre-infusion (n=414)	74.0 mm Hg Standard Deviation 10.09	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 197 DBP post-infusion (n=415)	74.4 mm Hg Standard Deviation 10.27	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 225 DBP pre-infusion (n=340)	73.9 mm Hg Standard Deviation 10.28	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 225 DBP post-infusion (n=338)	73.7 mm Hg Standard Deviation 9.53	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 253 DBP pre-infusion (n=251)	74.5 mm Hg Standard Deviation 10.60	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 253 DBP post-infusion (n=251)	74.5 mm Hg Standard Deviation 10.04	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 281 DBP pre-infusion (n=203)	74.7 mm Hg Standard Deviation 10.16	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 281 DBP post-infusion (n=202)	75.3 mm Hg Standard Deviation 9.94	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 309 DBP pre-infusion (n=160)	75.4 mm Hg Standard Deviation 10.36	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 309 DBP post-infusion (n=159)	75.6 mm Hg Standard Deviation 10.73	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 337 DBP pre-infusion (n=128)	74.5 mm Hg Standard Deviation 10.42	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 337 DBP post-infusion (n=128)	74.5 mm Hg Standard Deviation 10.48	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 365 DBP pre-infusion (n=118)	76.4 mm Hg Standard Deviation 10.88	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 365 DBP post-infusion (n=120)	75.0 mm Hg Standard Deviation 10.27	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 393 DBP pre-infusion (n=101)	75.3 mm Hg Standard Deviation 12.13	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 393 DBP post-infusion (n=99)	74.7 mm Hg Standard Deviation 10.77	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 421 DBP post-infusion (n=93)	75.5 mm Hg Standard Deviation 10.48	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 449 DBP pre-infusion (n=82)	75.8 mm Hg Standard Deviation 10.82	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 449 DBP post-infusion (n=82)	76.6 mm Hg Standard Deviation 11.73	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 477 DBP pre-infusion (n=75)	76.4 mm Hg Standard Deviation 13.25	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 477 DBP post-infusion (n=75)	75.2 mm Hg Standard Deviation 11.56	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 505 DBP pre-infusion (n=72)	75.3 mm Hg Standard Deviation 12.80	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 505 DBP post-infusion (n=73)	75.9 mm Hg Standard Deviation 13.62	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 533 DBP pre-infusion (n=67)	75.6 mm Hg Standard Deviation 11.36	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 533 DBP post-infusion (n=66)	77.0 mm Hg Standard Deviation 11.57	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 561 DBP pre-infusion (n=63)	74.9 mm Hg Standard Deviation 12.10	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 561 DBP post-infusion (n=63)	73.2 mm Hg Standard Deviation 12.32	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 589 DBP pre-infusion (n=57)	72.8 mm Hg Standard Deviation 12.0	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 589 DBP post-infusion (n=57)	74.7 mm Hg Standard Deviation 11.20	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 617 DBP pre-infusion (n=56)	74.4 mm Hg Standard Deviation 10.92	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 617 DBP post-infusion (n=55)	74.7 mm Hg Standard Deviation 12.53	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 645 DBP pre-infusion (n=44)	73.8 mm Hg Standard Deviation 10.68	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 645 DBP post-infusion (n=43)	76.2 mm Hg Standard Deviation 11.01	—
Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time Day 673 DBP pre-infusion (n=40)	76.3 mm Hg Standard Deviation 10.32	—

PRIMARY outcome

Timeframe: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept

Population: All treated participants. n=number of participants with evaluable heart rate readings.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=481 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Mean Heart Rate (HR) Over Time Day 169 HR pre-infusion (n=481)	74.4 beats per minute Standard Deviation 11.08	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 169 HR post-infusion (n=481)	73.0 beats per minute Standard Deviation 10.22	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 197 HR pre-infusion (n=414)	74.4 beats per minute Standard Deviation 11.58	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 197 HR post-infusion (n=416)	72.8 beats per minute Standard Deviation 10.65	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 225 HR pre-infusion (n=340)	74.7 beats per minute Standard Deviation 10.43	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 225 HR post-infusion (n=338)	72.5 beats per minute Standard Deviation 9.88	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 253 HR pre-infusion (n=252)	73.9 beats per minute Standard Deviation 11.72	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 253 HR post-infusion (n=252)	72.1 beats per minute Standard Deviation 10.96	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 281 HR pre-infusion (n=203)	73.8 beats per minute Standard Deviation 11.39	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 281 HR post-infusion (n=202)	72.4 beats per minute Standard Deviation 10.17	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 309 HR pre-infusion (n=160)	73.9 beats per minute Standard Deviation 9.62	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 309 HR post-infusion (n=159)	72.0 beats per minute Standard Deviation 9.85	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 337 HR pre-infusion (n=128)	74.1 beats per minute Standard Deviation 11.71	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 337 HR post-infusion (n=129)	70.9 beats per minute Standard Deviation 8.78	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 365 HR pre-infusion (n=118)	73.7 beats per minute Standard Deviation 12.20	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 365 HR post-infusion (n=120)	73.1 beats per minute Standard Deviation 10.21	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 393 HR pre-infusion (n=101)	73.0 beats per minute Standard Deviation 10.26	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 393 HR post-infusion (n=99)	72.4 beats per minute Standard Deviation 9.88	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 421 HR post-infusion (n=93)	71.6 beats per minute Standard Deviation 8.63	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 449 HR pre-infusion (n=82)	74.2 beats per minute Standard Deviation 10.67	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 449 HR post-infusion (n=82)	73.7 beats per minute Standard Deviation 9.81	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 477 HR pre-infusion (n=74)	75.4 beats per minute Standard Deviation 12.48	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 477 HR post-infusion (n=75)	72.9 beats per minute Standard Deviation 10.89	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 505 HR pre-infusion (n=72)	73.8 beats per minute Standard Deviation 11.41	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 505 HR post-infusion (n=73)	73.0 beats per minute Standard Deviation 8.90	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 533 HR pre-infusion (n=66)	73.2 beats per minute Standard Deviation 11.57	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 533 HR post-infusion (n=66)	75.7 beats per minute Standard Deviation 12.21	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 561 HR pre-infusion (n=63)	73.8 beats per minute Standard Deviation 10.09	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 561 HR post-infusion (n=63)	72.3 beats per minute Standard Deviation 10.18	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 589 HR pre-infusion (n=57)	73.0 beats per minute Standard Deviation 9.83	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 589 HR post-infusion (n=57)	71.5 beats per minute Standard Deviation 9.66	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 617 HR pre-infusion (n=56)	72.9 beats per minute Standard Deviation 10.89	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 617 HR post-infusion (n=55)	71.7 beats per minute Standard Deviation 9.40	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 645 HR pre-infusion (n=44)	76.6 beats per minute Standard Deviation 13.40	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 645 HR post-infusion (n=43)	76.1 beats per minute Standard Deviation 13.00	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 673 HR pre-infusion (n=40)	73.5 beats per minute Standard Deviation 11.67	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 673 HR post-infusion (n=41)	73.3 beats per minute Standard Deviation 10.74	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 701 HR pre-infusion (n=35)	72.1 beats per minute Standard Deviation 12.13	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 701 HR post-infusion (n=36)	73.3 beats per minute Standard Deviation 10.23	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 729 HR pre-infusion (n=32)	70.7 beats per minute Standard Deviation 11.24	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 729 HR post-infusion (n=32)	71.7 beats per minute Standard Deviation 11.38	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 757 HR pre-infusion (n=30)	74.1 beats per minute Standard Deviation 9.60	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 757 HR post-infusion (n=30)	73.2 beats per minute Standard Deviation 9.35	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 785 HR pre-infusion (n=25)	76.5 beats per minute Standard Deviation 8.78	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 785 HR post-infusion (n=25)	73.4 beats per minute Standard Deviation 8.61	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 813 HR pre-infusion (n=23)	73.9 beats per minute Standard Deviation 11.23	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 813 HR post-infusion (n=22)	71.4 beats per minute Standard Deviation 10.90	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 841 HR pre-infusion (n=19)	74.2 beats per minute Standard Deviation 10.95	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 841 HR post-infusion (n=19)	71.4 beats per minute Standard Deviation 9.15	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 869 HR pre-infusion (n=19)	72.4 beats per minute Standard Deviation 12.21	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 869 HR post-infusion (n=18)	72.3 beats per minute Standard Deviation 11.98	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 897 HR pre-infusion (n=19)	71.7 beats per minute Standard Deviation 9.16	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 897 HR post-infusion (n=19)	70.9 beats per minute Standard Deviation 9.10	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 925 HR pre-infusion (n=19)	76.7 beats per minute Standard Deviation 7.75	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 925 HR post-infusion (n=19)	73.0 beats per minute Standard Deviation 7.86	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 953 HR pre-infusion (n=19)	75.5 beats per minute Standard Deviation 10.57	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 953 HR post-infusion (n=19)	73.8 beats per minute Standard Deviation 7.49	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 981 HR pre-infusion (n=18)	75.7 beats per minute Standard Deviation 13.05	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 981 HR post-infusion (n=18)	72.8 beats per minute Standard Deviation 8.76	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 1009 HR pre-infusion (n=19)	76.1 beats per minute Standard Deviation 10.68	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 1009 HR post-infusion (n=18)	73.6 beats per minute Standard Deviation 7.94	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 1037 HR pre-infusion (n=15)	74.6 beats per minute Standard Deviation 11.36	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 1037 HR post-infusion (n=15)	75.1 beats per minute Standard Deviation 10.53	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 1065 HR pre-infusion (n=14)	74.3 beats per minute Standard Deviation 8.90	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 1065 HR post-infusion (n=14)	75.1 beats per minute Standard Deviation 9.05	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 1093 HR pre-infusion (n=10)	70.6 beats per minute Standard Deviation 9.54	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 1093 HR post-infusion (n=10)	70.3 beats per minute Standard Deviation 8.03	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 1121 HR pre-infusion (n=7)	72.4 beats per minute Standard Deviation 4.89	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 1121 HR post-infusion (n=7)	69.1 beats per minute Standard Deviation 3.80	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 1149 HR pre-infusion (n=7)	71.0 beats per minute Standard Deviation 1.83	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 1149 HR post-infusion (n=7)	69.9 beats per minute Standard Deviation 4.85	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 1177 HR pre-infusion (n=7)	75.0 beats per minute Standard Deviation 8.85	—
Long-term Period: Mean Heart Rate (HR) Over Time Day 1177 HR post-infusion (n=7)	69.1 beats per minute Standard Deviation 10.71	—

PRIMARY outcome

Timeframe: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept

Population: All treated participants. n=number of participants with evaluable temperature readings.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=482 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Mean Temperature (T) Over Time Day 897 T post-infusion (n=18)	36.3 degrees Celsius Standard Deviation 0.64	—
Long-term Period: Mean Temperature (T) Over Time Day 925 T pre-infusion (n=19)	36.1 degrees Celsius Standard Deviation 0.36	—
Long-term Period: Mean Temperature (T) Over Time Day 169 T pre-infusion (n=482)	36.5 degrees Celsius Standard Deviation 0.45	—
Long-term Period: Mean Temperature (T) Over Time Day 169 T post-infusion (n=478)	36.5 degrees Celsius Standard Deviation 0.45	—
Long-term Period: Mean Temperature (T) Over Time Day 197 T pre-infusion (n=415)	36.6 degrees Celsius Standard Deviation 0.44	—
Long-term Period: Mean Temperature (T) Over Time Day 197 T post-infusion (n=413)	36.5 degrees Celsius Standard Deviation 0.43	—
Long-term Period: Mean Temperature (T) Over Time Day 225 T pre-infusion (n=340)	36.5 degrees Celsius Standard Deviation 0.48	—
Long-term Period: Mean Temperature (T) Over Time Day 225 T post-infusion (n=335)	36.5 degrees Celsius Standard Deviation 0.46	—
Long-term Period: Mean Temperature (T) Over Time Day 253 T pre-infusion (n=251)	36.5 degrees Celsius Standard Deviation 0.48	—
Long-term Period: Mean Temperature (T) Over Time Day 253 T post-infusion (n=251)	36.5 degrees Celsius Standard Deviation 0.45	—
Long-term Period: Mean Temperature (T) Over Time Day 281 T pre-infusion (n=202)	36.4 degrees Celsius Standard Deviation 0.47	—
Long-term Period: Mean Temperature (T) Over Time Day 281 T post-infusion (n=202)	36.5 degrees Celsius Standard Deviation 0.45	—
Long-term Period: Mean Temperature (T) Over Time Day 309 T pre-infusion (n=158)	36.4 degrees Celsius Standard Deviation 0.48	—
Long-term Period: Mean Temperature (T) Over Time Day 309 T post-infusion (n=158)	36.4 degrees Celsius Standard Deviation 0.50	—
Long-term Period: Mean Temperature (T) Over Time Day 337 T pre-infusion (n=129)	36.3 degrees Celsius Standard Deviation 0.51	—
Long-term Period: Mean Temperature (T) Over Time Day 337 T post-infusion (n=128)	36.4 degrees Celsius Standard Deviation 0.49	—
Long-term Period: Mean Temperature (T) Over Time Day 365 T pre-infusion (n=118)	36.4 degrees Celsius Standard Deviation 0.54	—
Long-term Period: Mean Temperature (T) Over Time Day 365 T post-infusion (n=119)	36.4 degrees Celsius Standard Deviation 0.55	—
Long-term Period: Mean Temperature (T) Over Time Day 393 T pre-infusion (n=101)	36.4 degrees Celsius Standard Deviation 0.47	—
Long-term Period: Mean Temperature (T) Over Time Day 393 T post-infusion (n=96)	36.4 degrees Celsius Standard Deviation 0.50	—
Long-term Period: Mean Temperature (T) Over Time Day 421 T post-infusion (n=93)	36.4 degrees Celsius Standard Deviation 0.45	—
Long-term Period: Mean Temperature (T) Over Time Day 449 T pre-infusion (n=82)	36.4 degrees Celsius Standard Deviation 0.44	—
Long-term Period: Mean Temperature (T) Over Time Day 449 T post-infusion (n=82)	36.4 degrees Celsius Standard Deviation 0.48	—
Long-term Period: Mean Temperature (T) Over Time Day 477 T pre-infusion (n=75)	36.4 degrees Celsius Standard Deviation 0.51	—
Long-term Period: Mean Temperature (T) Over Time Day 477 T post-infusion (n=75)	36.4 degrees Celsius Standard Deviation 0.53	—
Long-term Period: Mean Temperature (T) Over Time Day 505 T pre-infusion (n=71)	36.5 degrees Celsius Standard Deviation 0.44	—
Long-term Period: Mean Temperature (T) Over Time Day 505 T post-infusion (n=72)	36.5 degrees Celsius Standard Deviation 0.55	—
Long-term Period: Mean Temperature (T) Over Time Day 533 T pre-infusion (n=67)	36.4 degrees Celsius Standard Deviation 0.57	—
Long-term Period: Mean Temperature (T) Over Time Day 533 T post-infusion (n=64)	36.4 degrees Celsius Standard Deviation 0.42	—
Long-term Period: Mean Temperature (T) Over Time Day 561 T pre-infusion (n=63)	36.4 degrees Celsius Standard Deviation 0.41	—
Long-term Period: Mean Temperature (T) Over Time Day 561 T post-infusion (n=62)	36.5 degrees Celsius Standard Deviation 0.43	—
Long-term Period: Mean Temperature (T) Over Time Day 589 T pre-infusion (n=57)	36.4 degrees Celsius Standard Deviation 0.50	—
Long-term Period: Mean Temperature (T) Over Time Day 589 T post-infusion (n=57)	36.4 degrees Celsius Standard Deviation 0.47	—
Long-term Period: Mean Temperature (T) Over Time Day 617 T pre-infusion (n=56)	36.4 degrees Celsius Standard Deviation 0.51	—
Long-term Period: Mean Temperature (T) Over Time Day 617 T post-infusion (n=54)	36.4 degrees Celsius Standard Deviation 0.43	—
Long-term Period: Mean Temperature (T) Over Time Day 645 T pre-infusion (n=44)	36.3 degrees Celsius Standard Deviation 0.47	—
Long-term Period: Mean Temperature (T) Over Time Day 645 T post-infusion (n=42)	36.3 degrees Celsius Standard Deviation 0.63	—
Long-term Period: Mean Temperature (T) Over Time Day 673 T pre-infusion (n=40)	36.3 degrees Celsius Standard Deviation 0.56	—
Long-term Period: Mean Temperature (T) Over Time Day 673 T post-infusion (n=41)	36.3 degrees Celsius Standard Deviation 0.50	—
Long-term Period: Mean Temperature (T) Over Time Day 701 T pre-infusion (n=35)	36.3 degrees Celsius Standard Deviation 0.49	—
Long-term Period: Mean Temperature (T) Over Time Day 701 T post-infusion (n=35)	36.3 degrees Celsius Standard Deviation 0.44	—
Long-term Period: Mean Temperature (T) Over Time Day 729 T pre-infusion (n=31)	36.1 degrees Celsius Standard Deviation 0.51	—
Long-term Period: Mean Temperature (T) Over Time Day 729 T post-infusion (n=32)	36.2 degrees Celsius Standard Deviation 0.42	—
Long-term Period: Mean Temperature (T) Over Time Day 757 T pre-infusion (n=30)	36.2 degrees Celsius Standard Deviation 0.52	—
Long-term Period: Mean Temperature (T) Over Time Day 757 T post-infusion (n=30)	36.2 degrees Celsius Standard Deviation 0.53	—
Long-term Period: Mean Temperature (T) Over Time Day 785 T pre-infusion (n=25)	36.2 degrees Celsius Standard Deviation 0.40	—
Long-term Period: Mean Temperature (T) Over Time Day 785 T post-infusion (n=24)	36.2 degrees Celsius Standard Deviation 0.37	—
Long-term Period: Mean Temperature (T) Over Time Day 813 T pre-infusion (n=23)	36.1 degrees Celsius Standard Deviation 0.43	—
Long-term Period: Mean Temperature (T) Over Time Day 813 T post-infusion (n=22)	36.0 degrees Celsius Standard Deviation 0.34	—
Long-term Period: Mean Temperature (T) Over Time Day 841 T pre-infusion (n=19)	36.1 degrees Celsius Standard Deviation 0.40	—
Long-term Period: Mean Temperature (T) Over Time Day 841 T post-infusion (n=19)	36.2 degrees Celsius Standard Deviation 0.46	—
Long-term Period: Mean Temperature (T) Over Time Day 869 T pre-infusion (n=19)	36.1 degrees Celsius Standard Deviation 0.66	—
Long-term Period: Mean Temperature (T) Over Time Day 869 T post-infusion (n=18)	36.1 degrees Celsius Standard Deviation 0.57	—
Long-term Period: Mean Temperature (T) Over Time Day 897 T pre-infusion (n=18)	36.2 degrees Celsius Standard Deviation 0.62	—
Long-term Period: Mean Temperature (T) Over Time Day 925 T post-infusion (n=19)	36.1 degrees Celsius Standard Deviation 0.43	—
Long-term Period: Mean Temperature (T) Over Time Day 953 T pre-infusion (n=19)	36.1 degrees Celsius Standard Deviation 0.54	—
Long-term Period: Mean Temperature (T) Over Time Day 953 T post-infusion (n=18)	36.1 degrees Celsius Standard Deviation 0.52	—
Long-term Period: Mean Temperature (T) Over Time Day 981 T pre-infusion (n=17)	36.2 degrees Celsius Standard Deviation 0.48	—
Long-term Period: Mean Temperature (T) Over Time Day 981 T post-infusion (n=17)	36.0 degrees Celsius Standard Deviation 0.68	—
Long-term Period: Mean Temperature (T) Over Time Day 1009 T pre-infusion (n=19)	36.1 degrees Celsius Standard Deviation 0.40	—
Long-term Period: Mean Temperature (T) Over Time Day 1009 T post-infusion (n=17)	36.3 degrees Celsius Standard Deviation 0.44	—
Long-term Period: Mean Temperature (T) Over Time Day 1037 T pre-infusion (n=15)	36.1 degrees Celsius Standard Deviation 0.38	—
Long-term Period: Mean Temperature (T) Over Time Day 1037 T post-infusion (n=15)	36.1 degrees Celsius Standard Deviation 0.41	—
Long-term Period: Mean Temperature (T) Over Time Day 1065 T pre-infusion (n=14)	36.1 degrees Celsius Standard Deviation 0.80	—
Long-term Period: Mean Temperature (T) Over Time Day 1065 T post-infusion (n=14)	36.3 degrees Celsius Standard Deviation 0.58	—
Long-term Period: Mean Temperature (T) Over Time Day 1093 T pre-infusion (n=10)	36.1 degrees Celsius Standard Deviation 0.59	—
Long-term Period: Mean Temperature (T) Over Time Day 1093 T post-infusion (n=10)	36.2 degrees Celsius Standard Deviation 0.47	—
Long-term Period: Mean Temperature (T) Over Time Day 1121 T pre-infusion (n=7)	36.3 degrees Celsius Standard Deviation 0.40	—
Long-term Period: Mean Temperature (T) Over Time Day 1121 T post-infusion (n=7)	36.4 degrees Celsius Standard Deviation 0.33	—
Long-term Period: Mean Temperature (T) Over Time Day 1149 T pre-infusion (n=7)	36.3 degrees Celsius Standard Deviation 0.43	—
Long-term Period: Mean Temperature (T) Over Time Day 1149 T post-infusion (n=7)	36.3 degrees Celsius Standard Deviation 0.35	—
Long-term Period: Mean Temperature (T) Over Time Day 1177 T pre-infusion (n=7)	36.1 degrees Celsius Standard Deviation 0.54	—
Long-term Period: Mean Temperature (T) Over Time Day 1177 T post-infusion (n=7)	36.2 degrees Celsius Standard Deviation 0.38	—

SECONDARY outcome

Timeframe: BL, Day 169

Population: All treated participants.

The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (\> 5.1), low disease activity (\< 3.2) and remission (\< 2.6). A clinically significant response= decrease in DAS28 score of \>1.2 from baseline.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=449 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User n=597 Participants In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Short-term Period: Number of Participants With Clinically Meaningful Improvement (CMI) in Disease Activity Score (DAS 28), Low Disease Activity (LDAS), or Remission at Day 169 CMI	267 participants	320 participants
Short-term Period: Number of Participants With Clinically Meaningful Improvement (CMI) in Disease Activity Score (DAS 28), Low Disease Activity (LDAS), or Remission at Day 169 LDAS	101 participants	133 participants
Short-term Period: Number of Participants With Clinically Meaningful Improvement (CMI) in Disease Activity Score (DAS 28), Low Disease Activity (LDAS), or Remission at Day 169 Remission	54 participants	82 participants

SECONDARY outcome

Timeframe: BL (Day 0), Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

Population: All treated participants. n=number of evaluable participants.

The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (\> 5.1), low disease activity (\< 3.2) and remission (\< 2.6). Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=429 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User n=580 Participants In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Short-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Through 6 Month Open-Label BL (Day 0) for Day 15 cohort (n=429,570)	6.21 units on a scale Standard Deviation 0.73	6.17 units on a scale Standard Deviation 0.72
Short-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Through 6 Month Open-Label Day 15 visit (n=429,570)	5.46 units on a scale Standard Deviation 1.05	5.49 units on a scale Standard Deviation 1.12
Short-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Through 6 Month Open-Label BL (Day 0) for Day 29 cohort (n=426,580)	6.22 units on a scale Standard Deviation 0.72	6.17 units on a scale Standard Deviation 0.71
Short-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Through 6 Month Open-Label Day 29 visit (n=426,580)	5.05 units on a scale Standard Deviation 1.20	5.09 units on a scale Standard Deviation 1.25
Short-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Through 6 Month Open-Label BL (Day 0) for Day 57 cohort (n=425,563)	6.22 units on a scale Standard Deviation 0.74	6.16 units on a scale Standard Deviation 0.71
Short-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Through 6 Month Open-Label Day 57 visit (n=425,563)	4.65 units on a scale Standard Deviation 1.27	4.72 units on a scale Standard Deviation 1.30
Short-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Through 6 Month Open-Label BL (Day 0) for Day 85 cohort (n=403,542)	6.21 units on a scale Standard Deviation 0.73	6.16 units on a scale Standard Deviation 0.72
Short-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Through 6 Month Open-Label Day 85 visit (n=403,542)	4.44 units on a scale Standard Deviation 1.37	4.57 units on a scale Standard Deviation 1.35
Short-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Through 6 Month Open-Label BL (Day 0) for Day 113 cohort (n=393,516)	6.20 units on a scale Standard Deviation 0.73	6.15 units on a scale Standard Deviation 0.71
Short-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Through 6 Month Open-Label Day 113 visit (n=393,516)	4.24 units on a scale Standard Deviation 1.36	4.39 units on a scale Standard Deviation 1.41
Short-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Through 6 Month Open-Label BL (Day 0) for Day 141 cohort (n=372,493)	6.19 units on a scale Standard Deviation 0.74	6.16 units on a scale Standard Deviation 0.73
Short-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Through 6 Month Open-Label Day 141 visit (n=372,493)	4.19 units on a scale Standard Deviation 1.38	4.27 units on a scale Standard Deviation 1.39
Short-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Through 6 Month Open-Label BL (Day 0) for Day 169 cohort(n=369,468)	6.19 units on a scale Standard Deviation 0.73	6.15 units on a scale Standard Deviation 0.73
Short-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Through 6 Month Open-Label Day 169 visit (n=369,468)	4.16 units on a scale Standard Deviation 1.43	4.14 units on a scale Standard Deviation 1.47

SECONDARY outcome

Timeframe: BL (Day 0), Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

Population: All treated participants. n=number of evaluable participants.

The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (\> 5.1), low disease activity (\< 3.2) and remission (\< 2.6). Time-matched mean change from BL= Post-BL value - time-matched BL value, where the time-matched BL value represents the mean BL (Day 0) value for only that cohort of participants with measurements available at that post-BL visit.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=429 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User n=580 Participants In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Short-term Period: Mean Time-matched Change From Baseline (Day 0) in DAS 28 Through 6 Month Open-Label Change from BL (Day 0) to Day 15 visit (n=429,570)	-0.75 units on a scale Standard Deviation 0.04	-0.68 units on a scale Standard Deviation 0.04
Short-term Period: Mean Time-matched Change From Baseline (Day 0) in DAS 28 Through 6 Month Open-Label Change from BL (Day 0) to Day 29 visit (n=426,580)	-1.18 units on a scale Standard Deviation 0.05	-1.07 units on a scale Standard Deviation 0.05
Short-term Period: Mean Time-matched Change From Baseline (Day 0) in DAS 28 Through 6 Month Open-Label Change from BL (Day 0) to Day 57 visit (n=425,563)	-1.57 units on a scale Standard Deviation 0.06	-1.44 units on a scale Standard Deviation 0.05
Short-term Period: Mean Time-matched Change From Baseline (Day 0) in DAS 28 Through 6 Month Open-Label Change from BL (Day 0) to Day 85 visit (n=403,542)	-1.76 units on a scale Standard Deviation 0.06	-1.60 units on a scale Standard Deviation 0.05
Short-term Period: Mean Time-matched Change From Baseline (Day 0) in DAS 28 Through 6 Month Open-Label Change from BL (Day 0) to Day 113 visit(n=393,516)	-1.96 units on a scale Standard Deviation 0.07	-1.76 units on a scale Standard Deviation 0.06
Short-term Period: Mean Time-matched Change From Baseline (Day 0) in DAS 28 Through 6 Month Open-Label Change from BL (Day 0) to Day 141 visit(n=372,493)	-2.00 units on a scale Standard Deviation 0.07	-1.90 units on a scale Standard Deviation 0.06
Short-term Period: Mean Time-matched Change From Baseline (Day 0) in DAS 28 Through 6 Month Open-Label Change from BL (Day 0) to Day 169 visit(n=369,468)	-2.02 units on a scale Standard Deviation 0.07	-2.01 units on a scale Standard Deviation 0.07

SECONDARY outcome

Timeframe: BL, Day 169

Population: All treated participants

hs-CRP is a acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA). Levels of hs-CRP can be used to determine DAS28.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=376 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User n=476 Participants In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Short-term Period: Mean Change From Baseline to Day 169 in High Sensitivity C-Reactive Protein (Hs-CRP)	-0.88 mg/dL Standard Deviation 0.13	-0.68 mg/dL Standard Deviation 0.13

SECONDARY outcome

Timeframe: BL, Day 169

Population: All treated participants

RF is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis. It is an antibody against the Fc portion of Immunoglobulin (Ig)G, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=376 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User n=476 Participants In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Short-term Period: Mean Change From Baseline to Day 169 in Rheumatoid Factor (RF)	-32.2 IU/mL Standard Deviation 11.33	-22.8 IU/mL Standard Deviation 10.19

SECONDARY outcome

Timeframe: BL, Day 169

Population: All treated participants

The HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. HAQ-DI= sum of worst scores in each domain divided by the number of domains answered. HAQ-DI ranges from a minimum of 0 (no difficulty) to a maximum overall score of 3(unable to do).

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=366 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User n=475 Participants In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Short-term Period: Mean Change From Baseline to Day 169 in the Health Assessment Questionnaire Disability Index (HAQ-DI)	-0.34 units on a scale Standard Deviation 0.03	-0.41 units on a scale Standard Deviation 0.03

SECONDARY outcome

Timeframe: BL, Day 169

Population: All treated participants

HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. HAQ-DI= sum of worst scores in each domain divided by the number of domains answered. HAQ-DI ranges from a minimum of 0 (no difficulty) to a maximum overall score of 3(unable to do). Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=449 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User n=597 Participants In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Short-term Period: Number of Participants Achieving a Clinically Meaningful HAQ Response	208 participants	281 participants

SECONDARY outcome

Timeframe: BL

Population: All treated participants. n=number of evaluable participants.

The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=370 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User n=475 Participants In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Short-term Period: Mean Baseline Short Form 36 (SF-36) Quality of Life Physical Component Summary (PCS), Mental Component Summary (MCS), and SF-36 Individual Component Scores PCS (n=360, n=466)	28.81 units on a scale Standard Deviation 7.74	28.75 units on a scale Standard Deviation 7.47
Short-term Period: Mean Baseline Short Form 36 (SF-36) Quality of Life Physical Component Summary (PCS), Mental Component Summary (MCS), and SF-36 Individual Component Scores MCS (n=360, n=466)	42.45 units on a scale Standard Deviation 12.98	42.43 units on a scale Standard Deviation 12.43
Short-term Period: Mean Baseline Short Form 36 (SF-36) Quality of Life Physical Component Summary (PCS), Mental Component Summary (MCS), and SF-36 Individual Component Scores Physical Function Scale Component (n=367, n=473)	27.72 units on a scale Standard Deviation 9.87	28.22 units on a scale Standard Deviation 9.54
Short-term Period: Mean Baseline Short Form 36 (SF-36) Quality of Life Physical Component Summary (PCS), Mental Component Summary (MCS), and SF-36 Individual Component Scores Role-Physical Scale Component (n=364, n=473)	32.06 units on a scale Standard Deviation 7.95	31.38 units on a scale Standard Deviation 7.11
Short-term Period: Mean Baseline Short Form 36 (SF-36) Quality of Life Physical Component Summary (PCS), Mental Component Summary (MCS), and SF-36 Individual Component Scores Bodily Pain Scale Component (n=367, n=472)	31.73 units on a scale Standard Deviation 7.17	31.13 units on a scale Standard Deviation 7.26
Short-term Period: Mean Baseline Short Form 36 (SF-36) Quality of Life Physical Component Summary (PCS), Mental Component Summary (MCS), and SF-36 Individual Component Scores General Health Scale Component (n=369, n=475)	35.70 units on a scale Standard Deviation 9.40	35.71 units on a scale Standard Deviation 9.22
Short-term Period: Mean Baseline Short Form 36 (SF-36) Quality of Life Physical Component Summary (PCS), Mental Component Summary (MCS), and SF-36 Individual Component Scores Vitality Scale Component (n=369, n=472)	35.95 units on a scale Standard Deviation 9.21	36.62 units on a scale Standard Deviation 9.11
Short-term Period: Mean Baseline Short Form 36 (SF-36) Quality of Life Physical Component Summary (PCS), Mental Component Summary (MCS), and SF-36 Individual Component Scores Social Functioning Scale Component (n=370, n=475)	34.76 units on a scale Standard Deviation 11.86	34.13 units on a scale Standard Deviation 10.99
Short-term Period: Mean Baseline Short Form 36 (SF-36) Quality of Life Physical Component Summary (PCS), Mental Component Summary (MCS), and SF-36 Individual Component Scores Role-Emotional Scale Component (n=365, n=471)	37.21 units on a scale Standard Deviation 13.99	36.98 units on a scale Standard Deviation 14.03
Short-term Period: Mean Baseline Short Form 36 (SF-36) Quality of Life Physical Component Summary (PCS), Mental Component Summary (MCS), and SF-36 Individual Component Scores Mental Health Scale Component (n=369, n=472)	41.79 units on a scale Standard Deviation 12.79	41.92 units on a scale Standard Deviation 11.95

SECONDARY outcome

Timeframe: BL, Day 169

Population: All treated participants. n=number of evaluable participants.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=370 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User n=475 Participants In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Short-term Period: Mean Change From Baseline to Day 169 in SF-36 PCS, MCS, and SF-36 Individual Component Scores PCS (n=360, n=466)	5.50 units on a scale Standard Deviation 0.44	6.08 units on a scale Standard Deviation 0.43
Short-term Period: Mean Change From Baseline to Day 169 in SF-36 PCS, MCS, and SF-36 Individual Component Scores MCS (n=360, n=466)	4.79 units on a scale Standard Deviation 0.59	5.43 units on a scale Standard Deviation 0.52
Short-term Period: Mean Change From Baseline to Day 169 in SF-36 PCS, MCS, and SF-36 Individual Component Scores Physical Function Scale Component (n=367, n=473)	4.31 units on a scale Standard Deviation 0.52	4.66 units on a scale Standard Deviation 0.49
Short-term Period: Mean Change From Baseline to Day 169 in SF-36 PCS, MCS, and SF-36 Individual Component Scores Role-Physical Scale Component (n=364, n=473)	5.85 units on a scale Standard Deviation 0.59	6.82 units on a scale Standard Deviation 0.55
Short-term Period: Mean Change From Baseline to Day 169 in SF-36 PCS, MCS, and SF-36 Individual Component Scores Bodily Pain Scale Component (n=367, n=472)	8.20 units on a scale Standard Deviation 0.45	8.72 units on a scale Standard Deviation 0.45
Short-term Period: Mean Change From Baseline to Day 169 in SF-36 PCS, MCS, and SF-36 Individual Component Scores General Health Scale Component (n=369, n=475)	2.85 units on a scale Standard Deviation 0.38	3.83 units on a scale Standard Deviation 0.38
Short-term Period: Mean Change From Baseline to Day 169 in SF-36 PCS, MCS, and SF-36 Individual Component Scores Vitality Scale Component (n=369, n=472)	6.32 units on a scale Standard Deviation 0.51	6.37 units on a scale Standard Deviation 0.50
Short-term Period: Mean Change From Baseline to Day 169 in SF-36 PCS, MCS, and SF-36 Individual Component Scores Social Functioning Scale Component (n=370, n=475)	6.44 units on a scale Standard Deviation 0.58	7.18 units on a scale Standard Deviation 0.54
Short-term Period: Mean Change From Baseline to Day 169 in SF-36 PCS, MCS, and SF-36 Individual Component Scores Role-Emotional Scale Component (n=365, n=471)	5.30 units on a scale Standard Deviation 0.76	5.85 units on a scale Standard Deviation 0.71
Short-term Period: Mean Change From Baseline to Day 169 in SF-36 PCS, MCS, and SF-36 Individual Component Scores Mental Health Scale Component (n=369, n=472)	3.74 units on a scale Standard Deviation 0.52	4.41 units on a scale Standard Deviation 0.46

SECONDARY outcome

Timeframe: BL

Population: All treated participants

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=376 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User n=476 Participants In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Short-term Period: Mean Baseline Fatigue Visual Analog Scale (VAS)	73.33 units on a scale Standard Deviation 19.67	72.70 units on a scale Standard Deviation 20.75

SECONDARY outcome

Timeframe: BL, Day 169

Population: All treated participants

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=376 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User n=476 Participants In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Short-term Period: Mean Change From Baseline to Day 169 in Fatigue Visual Analog Scale (VAS)	-18.3 units on a scale Standard Deviation 1.35	-20.2 units on a scale Standard Deviation 1.25

SECONDARY outcome

Timeframe: BL, Days 365, 449, 533, 617, 729, 813

Population: All treated participants. n=number of evaluable participants.

The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (\> 5.1), low disease activity (\< 3.2) and remission (\< 2.6). A clinically significant response= decrease in DAS28 score of \>1.2 from baseline.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=213 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Number of Participants With Clinically Meaningful Improvement in DAS 28, Low Disease Activity, or Remission Over Time Day 729 Remission (n=60)	12 participants	—
Long-term Period: Number of Participants With Clinically Meaningful Improvement in DAS 28, Low Disease Activity, or Remission Over Time Day 365 CMI (n=212)	163 participants	—
Long-term Period: Number of Participants With Clinically Meaningful Improvement in DAS 28, Low Disease Activity, or Remission Over Time Day 365 LDAS (n=213)	70 participants	—
Long-term Period: Number of Participants With Clinically Meaningful Improvement in DAS 28, Low Disease Activity, or Remission Over Time Day 365 Remission (n=213)	31 participants	—
Long-term Period: Number of Participants With Clinically Meaningful Improvement in DAS 28, Low Disease Activity, or Remission Over Time Day 449 CMI (n=119)	105 participants	—
Long-term Period: Number of Participants With Clinically Meaningful Improvement in DAS 28, Low Disease Activity, or Remission Over Time Day 449 LDAS (n=120)	43 participants	—
Long-term Period: Number of Participants With Clinically Meaningful Improvement in DAS 28, Low Disease Activity, or Remission Over Time Day 449 Remission (n=120)	25 participants	—
Long-term Period: Number of Participants With Clinically Meaningful Improvement in DAS 28, Low Disease Activity, or Remission Over Time Day 533 CMI (n=102)	91 participants	—
Long-term Period: Number of Participants With Clinically Meaningful Improvement in DAS 28, Low Disease Activity, or Remission Over Time Day 533 LDAS (n=102)	38 participants	—
Long-term Period: Number of Participants With Clinically Meaningful Improvement in DAS 28, Low Disease Activity, or Remission Over Time Day 533 Remission (n=102)	25 participants	—
Long-term Period: Number of Participants With Clinically Meaningful Improvement in DAS 28, Low Disease Activity, or Remission Over Time Day 617 CMI (n=78)	69 participants	—
Long-term Period: Number of Participants With Clinically Meaningful Improvement in DAS 28, Low Disease Activity, or Remission Over Time Day 617 LDAS (n=79)	38 participants	—
Long-term Period: Number of Participants With Clinically Meaningful Improvement in DAS 28, Low Disease Activity, or Remission Over Time Day 617 Remission (79)	17 participants	—
Long-term Period: Number of Participants With Clinically Meaningful Improvement in DAS 28, Low Disease Activity, or Remission Over Time Day 729 CMI (n=59)	51 participants	—
Long-term Period: Number of Participants With Clinically Meaningful Improvement in DAS 28, Low Disease Activity, or Remission Over Time Day 729 LDAS (n=60)	23 participants	—
Long-term Period: Number of Participants With Clinically Meaningful Improvement in DAS 28, Low Disease Activity, or Remission Over Time Day 813 CMI (n=38)	34 participants	—
Long-term Period: Number of Participants With Clinically Meaningful Improvement in DAS 28, Low Disease Activity, or Remission Over Time Day 813 LDAS (n=38)	21 participants	—
Long-term Period: Number of Participants With Clinically Meaningful Improvement in DAS 28, Low Disease Activity, or Remission Over Time Day 813 Remission (n=38)	12 participants	—

SECONDARY outcome

Timeframe: BL (Day 0), Days 365, 449, 533, 617, 729, 813

Population: All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time

The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (\> 5.1), low disease activity (\< 3.2) and remission (\< 2.6). Time-matched baseline (Day 0)values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=212 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Over the Long Term BL (Day 0) for Day 365 cohort (n=212)	6.18 units on a scale Standard Deviation 0.73	—
Long-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Over the Long Term Day 365 visit (n=212)	3.90 units on a scale Standard Deviation 1.32	—
Long-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Over the Long Term BL (Day 0) for Day 449 cohort (n=212)	6.16 units on a scale Standard Deviation 0.70	—
Long-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Over the Long Term Day 449 visit (n=212)	3.55 units on a scale Standard Deviation 1.11	—
Long-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Over the Long Term BL (Day 0) for Day 533 cohort (n=102)	6.16 units on a scale Standard Deviation 0.73	—
Long-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Over the Long Term Day 533 visit (n=102)	3.52 units on a scale Standard Deviation 1.09	—
Long-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Over the Long Term BL (Day 0) for Day 617 cohort (n=78)	6.15 units on a scale Standard Deviation 0.68	—
Long-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Over the Long Term Day 617 visit (n=78)	3.44 units on a scale Standard Deviation 1.12	—
Long-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Over the Long Term BL (Day 0) for Day 729 cohort (n=59)	6.16 units on a scale Standard Deviation 0.69	—
Long-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Over the Long Term Day 729 visit (n=59)	3.49 units on a scale Standard Deviation 1.18	—
Long-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Over the Long Term BL (Day 0) for Day 813 cohort (n=38)	6.26 units on a scale Standard Deviation 0.67	—
Long-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Over the Long Term Day 813 visit (n=38)	3.28 units on a scale Standard Deviation 1.07	—

SECONDARY outcome

Timeframe: BL (Day 0), Days 365, 449, 533, 617, 729, 813

The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (\> 5.1), low disease activity (\< 3.2) and remission (\< 2.6). Time-matched mean change from BL= Post-BL value - time-matched BL value, where the time-matched BL value represents the mean BL(Day 0)value for only that cohort of participants with measurements available at that post-BL visit.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=212 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in DAS 28 Over The Long Term Change from BL (Day 0) to Day 365 visit (n=212)	-2.28 units on a scale Standard Error 0.10	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in DAS 28 Over The Long Term Change from BL (Day 0) to Day 449 visit (n=212)	-2.62 units on a scale Standard Error 0.11	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in DAS 28 Over The Long Term Change from BL (Day 0) to Day 533 visit (n=102)	-2.64 units on a scale Standard Error 0.13	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in DAS 28 Over The Long Term Change from BL (Day 0) to Day 617 visit (n=78)	-2.72 units on a scale Standard Error 0.15	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in DAS 28 Over The Long Term Change from BL (Day 0) to Day 729 visit (n=59)	-2.66 units on a scale Standard Error 0.19	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in DAS 28 Over The Long Term Change from BL (Day 0) to Day 813 visit (n=38)	-2.97 units on a scale Standard Error 0.22	—

SECONDARY outcome

Timeframe: BL (Day 0), Days 365, 449, 533, 617, 729, 813

The mean number of tender joints was evaluated based on the number of tender joints in a standard 68 joint count. Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=221 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Tender Joints and Number of Tender Joints for Post-Baseline Visits Over the Long Term BL (Day 0) for Day 365 cohort (n=221)	16.90 tender joints Standard Deviation 5.82	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Tender Joints and Number of Tender Joints for Post-Baseline Visits Over the Long Term Day 365 visit (n=221)	6.04 tender joints Standard Deviation 6.75	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Tender Joints and Number of Tender Joints for Post-Baseline Visits Over the Long Term BL (Day 0) for Day 449 cohort (n=221)	16.57 tender joints Standard Deviation 5.68	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Tender Joints and Number of Tender Joints for Post-Baseline Visits Over the Long Term Day 449 visit (n=221)	4.39 tender joints Standard Deviation 5.17	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Tender Joints and Number of Tender Joints for Post-Baseline Visits Over the Long Term BL (Day 0) for Day 533 cohort (n=107)	16.14 tender joints Standard Deviation 5.81	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Tender Joints and Number of Tender Joints for Post-Baseline Visits Over the Long Term Day 533 visit (n=107)	4.34 tender joints Standard Deviation 4.83	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Tender Joints and Number of Tender Joints for Post-Baseline Visits Over the Long Term BL (Day 0) for Day 617 cohort (n=87)	16.29 tender joints Standard Deviation 5.75	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Tender Joints and Number of Tender Joints for Post-Baseline Visits Over the Long Term Day 617 visit (n=87)	3.75 tender joints Standard Deviation 4.75	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Tender Joints and Number of Tender Joints for Post-Baseline Visits Over the Long Term BL (Day 0) for Day 729 cohort (n=63)	16.40 tender joints Standard Deviation 5.97	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Tender Joints and Number of Tender Joints for Post-Baseline Visits Over the Long Term Day 729 visit (n=63)	4.02 tender joints Standard Deviation 5.08	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Tender Joints and Number of Tender Joints for Post-Baseline Visits Over the Long Term BL (Day 0) for Day 813 cohort (n=43)	17.42 tender joints Standard Deviation 5.57	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Tender Joints and Number of Tender Joints for Post-Baseline Visits Over the Long Term Day 813 visit (n=43)	3.67 tender joints Standard Deviation 4.04	—

SECONDARY outcome

Timeframe: BL (Day 0), Days 365, 449, 533, 617, 729, 813

The mean number of tender joints was evaluated based on the number of tender joints in a standard 68 joint count. Time-matched mean change from baseline = Post-baseline value - time-matched baseline value, where the time-matched baseline value represents the mean baseline (Day 0) value for only that cohort of participants with measurements available at that post-baseline visit.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=221 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in Number of Tender Joints Over the Long Term Change from BL (Day 0) to Day 365 visit (n=221)	-10.9 tender joints Standard Error 0.51	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in Number of Tender Joints Over the Long Term Change from BL (Day 0) to Day 449 visit (n=221)	-12.2 tender joints Standard Error 0.58	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in Number of Tender Joints Over the Long Term Change from BL (Day 0) to Day 533 visit (n=107)	-11.8 tender joints Standard Error 0.70	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in Number of Tender Joints Over the Long Term Change from BL (Day 0) to Day 617 visit (n=87)	-12.5 tender joints Standard Error 0.75	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in Number of Tender Joints Over the Long Term Change from BL (Day 0) to Day 729 visit (n=63)	-12.4 tender joints Standard Error 0.98	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in Number of Tender Joints Over the Long Term Change from BL (Day 0) to Day 813 visit (n=43)	-13.7 tender joints Standard Error 1.12	—

SECONDARY outcome

Timeframe: BL (Day 0), Days 365, 449, 533, 617, 729, 813

The mean number of swollen joints was evaluated based on the number of swollen joints in a standard 66 joint count. Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=221 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Swollen Joints And Post-Baseline Number of Swollen Joints Over the Long Term BL (Day 0) for Day 365 cohort (n=221)	12.72 swollen joints Standard Deviation 5.37	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Swollen Joints And Post-Baseline Number of Swollen Joints Over the Long Term Day 365 visit (n=221)	4.56 swollen joints Standard Deviation 4.83	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Swollen Joints And Post-Baseline Number of Swollen Joints Over the Long Term BL (Day 0) for Day 449 cohort (n=221)	12.50 swollen joints Standard Deviation 4.95	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Swollen Joints And Post-Baseline Number of Swollen Joints Over the Long Term Day 449 visit (n=221)	3.63 swollen joints Standard Deviation 3.99	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Swollen Joints And Post-Baseline Number of Swollen Joints Over the Long Term BL (Day 0) for Day 533 cohort (n=107)	11.91 swollen joints Standard Deviation 5.01	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Swollen Joints And Post-Baseline Number of Swollen Joints Over the Long Term Day 533 visit (n=107)	2.81 swollen joints Standard Deviation 2.67	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Swollen Joints And Post-Baseline Number of Swollen Joints Over the Long Term BL (Day 0) for Day 617 cohort (n=87)	11.98 swollen joints Standard Deviation 4.91	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Swollen Joints And Post-Baseline Number of Swollen Joints Over the Long Term Day 617 visit (n=87)	2.97 swollen joints Standard Deviation 3.40	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Swollen Joints And Post-Baseline Number of Swollen Joints Over the Long Term BL (Day 0) for Day 729 cohort (n=63)	11.57 swollen joints Standard Deviation 4.74	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Swollen Joints And Post-Baseline Number of Swollen Joints Over the Long Term Day 729 visit (n=63)	3.02 swollen joints Standard Deviation 4.05	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Swollen Joints And Post-Baseline Number of Swollen Joints Over the Long Term BL (Day 0) for Day 813 cohort (n=43)	12.40 swollen joints Standard Deviation 4.14	—
Long-term Period: Mean Time-matched Baseline (Day 0) Number of Swollen Joints And Post-Baseline Number of Swollen Joints Over the Long Term Day 813 visit (n=43)	2.14 swollen joints Standard Deviation 3.10	—

SECONDARY outcome

Timeframe: BL (Day 0), Days 365, 449, 533, 617, 729, 813

The mean number of swollen joints was evaluated based on the number of swollen joints in a standard 66 joint count. Time-matched mean change from baseline = Post-baseline value - time-matched baseline value, where the time-matched baseline value represents the mean baseline (Day 0) value for only that cohort of participants with measurements available at that post-baseline visit.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=221 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Mean Time-Matched Change From Baseline (Day 0) in Number of Swollen Joints Over the Long Term Change from BL (Day 0) to Day 365 visit (n=221)	-8.16 swollen joints Standard Error 0.40	—
Long-term Period: Mean Time-Matched Change From Baseline (Day 0) in Number of Swollen Joints Over the Long Term Change from BL (Day 0) to Day 449 visit (n=221)	-8.87 swollen joints Standard Error 0.48	—
Long-term Period: Mean Time-Matched Change From Baseline (Day 0) in Number of Swollen Joints Over the Long Term Change from BL (Day 0) to Day 533 visit (n=107)	-9.09 swollen joints Standard Error 0.50	—
Long-term Period: Mean Time-Matched Change From Baseline (Day 0) in Number of Swollen Joints Over the Long Term Change from BL (Day 0) to Day 617 visit (n=87)	-9.01 swollen joints Standard Error 0.60	—
Long-term Period: Mean Time-Matched Change From Baseline (Day 0) in Number of Swollen Joints Over the Long Term Change from BL (Day 0) to Day 729 visit (n=63)	-8.56 swollen joints Standard Error 0.81	—
Long-term Period: Mean Time-Matched Change From Baseline (Day 0) in Number of Swollen Joints Over the Long Term Change from BL (Day 0) to Day 813 visit (n=43)	-10.3 swollen joints Standard Error 0.76	—

SECONDARY outcome

Timeframe: BL (Day 0), Days 365, 449, 533, 617, 729, 813

hs-CRP is a acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA). Levels of hs-CRP can be used to determine DAS28. Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=216 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Mean Time-matched Baseline (Day 0) Hs-CRP Levels and Hs-CRP Levels for Post-Baseline Over the Long Term BL (Day 0) for Day 365 cohort (n=216)	2.36 mg/dL Standard Deviation 2.90	—
Long-term Period: Mean Time-matched Baseline (Day 0) Hs-CRP Levels and Hs-CRP Levels for Post-Baseline Over the Long Term Day 365 visit (n=216)	1.24 mg/dL Standard Deviation 1.78	—
Long-term Period: Mean Time-matched Baseline (Day 0) Hs-CRP Levels and Hs-CRP Levels for Post-Baseline Over the Long Term BL (Day 0) for Day 449 cohort (n=125)	2.48 mg/dL Standard Deviation 2.89	—
Long-term Period: Mean Time-matched Baseline (Day 0) Hs-CRP Levels and Hs-CRP Levels for Post-Baseline Over the Long Term Day 449 visit (n=125)	0.97 mg/dL Standard Deviation 1.59	—
Long-term Period: Mean Time-matched Baseline (Day 0) Hs-CRP Levels and Hs-CRP Levels for Post-Baseline Over the Long Term BL (Day 0) for Day 533 cohort (n=106)	2.65 mg/dL Standard Deviation 2.99	—
Long-term Period: Mean Time-matched Baseline (Day 0) Hs-CRP Levels and Hs-CRP Levels for Post-Baseline Over the Long Term Day 533 visit (n=106)	0.93 mg/dL Standard Deviation 1.39	—
Long-term Period: Mean Time-matched Baseline (Day 0) Hs-CRP Levels and Hs-CRP Levels for Post-Baseline Over the Long Term BL (Day 0) for Day 617 cohort (n=80)	2.82 mg/dL Standard Deviation 3.22	—
Long-term Period: Mean Time-matched Baseline (Day 0) Hs-CRP Levels and Hs-CRP Levels for Post-Baseline Over the Long Term Day 617 visit (n=80)	0.81 mg/dL Standard Deviation 1.21	—
Long-term Period: Mean Time-matched Baseline (Day 0) Hs-CRP Levels and Hs-CRP Levels for Post-Baseline Over the Long Term BL (Day 0) for Day 729 cohort (n=61)	2.47 mg/dL Standard Deviation 3.21	—
Long-term Period: Mean Time-matched Baseline (Day 0) Hs-CRP Levels and Hs-CRP Levels for Post-Baseline Over the Long Term Day 729 visit (n=61)	0.98 mg/dL Standard Deviation 1.57	—
Long-term Period: Mean Time-matched Baseline (Day 0) Hs-CRP Levels and Hs-CRP Levels for Post-Baseline Over the Long Term BL (Day 0) for Day 813 cohort (n=43)	2.60 mg/dL Standard Deviation 2.80	—
Long-term Period: Mean Time-matched Baseline (Day 0) Hs-CRP Levels and Hs-CRP Levels for Post-Baseline Over the Long Term Day 813 visit (n=43)	0.68 mg/dL Standard Deviation 0.96	—

SECONDARY outcome

Timeframe: BL (Day 0), Days 365, 449, 533, 617, 729, 813

hs-CRP is a acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA). Levels of hs-CRP can be used to determine DAS28. Time-matched mean change from baseline = Post-baseline value - time-matched baseline value, where the time-matched baseline value represents the mean baseline (Day 0) value for only that cohort of participants with measurements available at that post-baseline visit.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=216 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in Hs-CRP Level Over the Long Term Change from BL (Day 0) to Day 365 visit (n=216)	-1.12 mg/dL Standard Error 0.19	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in Hs-CRP Level Over the Long Term Change from BL (Day 0) to Day 449 visit (n=125)	-1.51 mg/dL Standard Error 0.22	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in Hs-CRP Level Over the Long Term Change from BL (Day 0) to Day 533 visit (n=106)	-1.72 mg/dL Standard Error 0.26	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in Hs-CRP Level Over the Long Term Change from BL (Day 0) to Day 617 visit (n=80)	-2.02 mg/dL Standard Error 0.32	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in Hs-CRP Level Over the Long Term Change from BL (Day 0) to Day 729 visit (n=61)	-1.49 mg/dL Standard Error 0.36	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in Hs-CRP Level Over the Long Term Change from BL (Day 0) to Day 813 visit (n=43)	-1.92 mg/dL Standard Error 0.43	—

SECONDARY outcome

Timeframe: BL (Day 0), Days 365, 449, 533, 617, 729, 813

The VAS for Fatigue (VAS-F) consists of a 100 mm line, with 0 (No Fatigue) on 1 end and 100 (Extreme Fatigue) on the other end, which a participant marks to indicate how much fatigue he or she feels. The marked point in mm is converted into a numeric value from 0 to 100, where 0=no fatigue and 100=maximum fatigue. Increasing numbers=increasing fatigue. Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=216 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Mean Time-matched Baseline (Day 0) Visual Analog Scale (VAS) and VAS for Post-Baseline Visits Over the Long Term BL (Day 0) for Day 365 cohort (n=220)	74.05 units on a scale Standard Deviation 16.28	—
Long-term Period: Mean Time-matched Baseline (Day 0) Visual Analog Scale (VAS) and VAS for Post-Baseline Visits Over the Long Term Day 365 visit (n=220)	40.61 units on a scale Standard Deviation 24.76	—
Long-term Period: Mean Time-matched Baseline (Day 0) Visual Analog Scale (VAS) and VAS for Post-Baseline Visits Over the Long Term BL (Day 0) for Day 449 cohort (n=121)	73.20 units on a scale Standard Deviation 15.46	—
Long-term Period: Mean Time-matched Baseline (Day 0) Visual Analog Scale (VAS) and VAS for Post-Baseline Visits Over the Long Term Day 449 visit (n=121)	38.74 units on a scale Standard Deviation 24.18	—
Long-term Period: Mean Time-matched Baseline (Day 0) Visual Analog Scale (VAS) and VAS for Post-Baseline Visits Over the Long Term BL (Day 0) for Day 533 cohort (n=104)	73.41 units on a scale Standard Deviation 15.51	—
Long-term Period: Mean Time-matched Baseline (Day 0) Visual Analog Scale (VAS) and VAS for Post-Baseline Visits Over the Long Term Day 533 visit (n=104)	39.27 units on a scale Standard Deviation 23.23	—
Long-term Period: Mean Time-matched Baseline (Day 0) Visual Analog Scale (VAS) and VAS for Post-Baseline Visits Over the Long Term BL (Day 0) for Day 617 cohort (n=85)	73.59 units on a scale Standard Deviation 14.75	—
Long-term Period: Mean Time-matched Baseline (Day 0) Visual Analog Scale (VAS) and VAS for Post-Baseline Visits Over the Long Term Day 617 visit (n=85)	42.16 units on a scale Standard Deviation 22.75	—
Long-term Period: Mean Time-matched Baseline (Day 0) Visual Analog Scale (VAS) and VAS for Post-Baseline Visits Over the Long Term BL (Day 0) for Day 729 cohort (n=61)	73.48 units on a scale Standard Deviation 16.71	—
Long-term Period: Mean Time-matched Baseline (Day 0) Visual Analog Scale (VAS) and VAS for Post-Baseline Visits Over the Long Term Day 729 visit (n=61)	42.90 units on a scale Standard Deviation 23.09	—
Long-term Period: Mean Time-matched Baseline (Day 0) Visual Analog Scale (VAS) and VAS for Post-Baseline Visits Over the Long Term BL (Day 0) for Day 813 cohort (n=38)	74.47 units on a scale Standard Deviation 16.68	—
Long-term Period: Mean Time-matched Baseline (Day 0) Visual Analog Scale (VAS) and VAS for Post-Baseline Visits Over the Long Term Day 813 visit (n=38)	39.61 units on a scale Standard Deviation 22.13	—

SECONDARY outcome

Timeframe: BL (Day 0), Days 365, 449, 533, 617, 729, 813

The VAS for Fatigue (VAS-F) consists of a 100 mm line, with 0 (No Fatigue) on 1 end and 100 (Extreme Fatigue) on the other end, which a participant marks to indicate how much fatigue he or she feels. The marked point in mm is converted into a numeric value from 0 to 100, where 0=no fatigue and 100=maximum fatigue. Increasing numbers=increasing fatigue. Time-matched mean change from BL = Post-BL value - time-matched BL value, where the time-matched BL value represents the mean BL (Day 0) value for only that cohort of participants with data available at that post-BL visit.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=216 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in VAS Over the Long Term Change from BL (Day 0) to Day 365 visit (n=220)	-33.4 units on a scale Standard Error 1.88	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in VAS Over the Long Term Change from BL (Day 0) to Day 449 visit (n=121)	-34.5 units on a scale Standard Error 2.43	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in VAS Over the Long Term Change from BL (Day 0) to Day 533 visit (n=104)	-34.1 units on a scale Standard Error 2.82	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in VAS Over the Long Term Change from BL (Day 0) to Day 617 visit (n=85)	-31.4 units on a scale Standard Error 2.91	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in VAS Over the Long Term Change from BL (Day 0) to Day 729 visit (n=61)	-30.6 units on a scale Standard Error 3.65	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in VAS Over the Long Term Change from BL (Day 0) to Day 813 visit (n=38)	-34.9 units on a scale Standard Error 4.03	—

SECONDARY outcome

Timeframe: BL (Day 0)

HAQ-DI includes 20 questions to assess physical functions in 8 domains:dressing, arising,eating,walking, hygiene, reach, grip and common activities. Domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. HAQ-DI= sum of worst scores in each domain divided by number of domains answered. HAQ-DI minimum=0 (no difficulty), max overall score=3(unable to do). Time-matched BL(Day 0)values presented for each post-BL visit represent only that cohort of participants with measurements available at that post-BL visit.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=216 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 HAQ gripping (n=63)	1.90 units on a scale Standard Deviation 0.73	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 HAQ activities (n=63)	2.03 units on a scale Standard Deviation 0.80	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 813 HAQ-DI (n=39)	2.01 units on a scale Standard Deviation 0.62	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 813 HAQ dressing and grooming (n=39)	1.92 units on a scale Standard Deviation 0.84	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 813 HAQ arising (n=39)	1.59 units on a scale Standard Deviation 0.75	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 813 HAQ eating (n=39)	2.18 units on a scale Standard Deviation 0.94	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 HAQ-DI (n=215)	1.80 units on a scale Standard Deviation 0.62	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 HAQ dressing and grooming (n=215)	1.62 units on a scale Standard Deviation 0.86	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 HAQ arising (n=215)	1.39 units on a scale Standard Deviation 0.76	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 HAQ eating (n=215)	1.84 units on a scale Standard Deviation 0.92	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 HAQ walking (n=215)	1.43 units on a scale Standard Deviation 0.78	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 HAQ hygiene (n=214)	2.08 units on a scale Standard Deviation 0.77	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 HAQ reaching (n=215)	2.12 units on a scale Standard Deviation 0.80	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 HAQ gripping (n=216)	1.94 units on a scale Standard Deviation 0.70	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 HAQ activities (n=216)	2.00 units on a scale Standard Deviation 0.80	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 449 HAQ-DI (n=116)	1.89 units on a scale Standard Deviation 0.60	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 449 HAQ dressing and grooming (n=116)	1.77 units on a scale Standard Deviation 0.81	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 449 HAQ arising (n=116)	1.45 units on a scale Standard Deviation 0.74	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 449 HAQ eating (n=116)	2.01 units on a scale Standard Deviation 0.90	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 449 HAQ walking (n=116)	1.53 units on a scale Standard Deviation 0.76	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 449 HAQ hygiene (n=117)	2.11 units on a scale Standard Deviation 0.77	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 449 HAQ reaching (n=117)	2.23 units on a scale Standard Deviation 0.77	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 449 HAQ gripping (n=117)	1.97 units on a scale Standard Deviation 0.68	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 449 HAQ activities (n=117)	2.05 units on a scale Standard Deviation 0.76	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 533 HAQ-DI (n=101)	1.87 units on a scale Standard Deviation 0.62	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 533 HAQ dressing and grooming (n=102)	1.78 units on a scale Standard Deviation 0.83	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 533 HAQ arising (n=102)	1.41 units on a scale Standard Deviation 0.76	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 533 HAQ eating (n=102)	1.96 units on a scale Standard Deviation 0.92	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 533 HAQ walking (n=102)	1.56 units on a scale Standard Deviation 0.74	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 533 HAQ hygiene (n=101)	2.07 units on a scale Standard Deviation 0.78	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 533 HAQ reaching (n=101)	2.22 units on a scale Standard Deviation 0.78	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 533 HAQ gripping (n=101)	1.96 units on a scale Standard Deviation 0.68	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 533 HAQ activities (n=101)	2.03 units on a scale Standard Deviation 0.79	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 617 HAQ-DI (n=83)	1.86 units on a scale Standard Deviation 0.61	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 617 HAQ dressing and grooming (n=83)	1.78 units on a scale Standard Deviation 0.81	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 617 HAQ arising (n=83)	1.40 units on a scale Standard Deviation 0.75	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 617 HAQ eating (n=83)	1.94 units on a scale Standard Deviation 0.90	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 617 HAQ walking (n=83)	1.54 units on a scale Standard Deviation 0.72	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 617 HAQ hygiene (n=83)	2.02 units on a scale Standard Deviation 0.76	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 617 HAQ reaching (n=83)	2.20 units on a scale Standard Deviation 0.78	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 617 HAQ gripping (n=83)	1.94 units on a scale Standard Deviation 0.69	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 617 HAQ activities (n=83)	2.04 units on a scale Standard Deviation 0.83	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 HAQ-DI (n=63)	1.86 units on a scale Standard Deviation 0.61	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 HAQ dressing and grooming (n=63)	1.75 units on a scale Standard Deviation 0.82	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 HAQ arising (n=63)	1.40 units on a scale Standard Deviation 0.75	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 HAQ eating (n=63)	1.95 units on a scale Standard Deviation 0.92	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 HAQ walking (n=63)	1.57 units on a scale Standard Deviation 0.67	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 HAQ hygiene (n=63)	2.00 units on a scale Standard Deviation 0.78	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 HAQ reaching (n=63)	2.24 units on a scale Standard Deviation 0.71	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 813 HAQ walking (n=39)	1.69 units on a scale Standard Deviation 0.66	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 813 HAQ hygiene (n=39)	2.10 units on a scale Standard Deviation 0.82	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 813 HAQ reaching (n=39)	2.41 units on a scale Standard Deviation 0.64	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 813 HAQ gripping (n=39)	2.00 units on a scale Standard Deviation 0.79	—
Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 813 HAQ activities (n=39)	2.18 units on a scale Standard Deviation 0.79	—

SECONDARY outcome

Timeframe: Days 365, 449, 533, 617, 729, 813

Population: All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean post-baseline values reflect changing n-values over time

HAQ-DI includes 20 questions to assess physical functions in 8 domains:dressing, arising, eating, walking, hygiene, reach, grip and common activities. Domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. HAQ-DI= sum of worst scores in each domain divided by number of domains answered. HAQ-DI minimum=0(no difficulty), max overall score=3(unable to do). Post-BL values presented for each visit represent only that cohort of participants with measurements available at that post-BL visit.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=216 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 813 HAQ eating (n=39)	1.46 units on a scale Standard Deviation 0.94	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 365 HAQ-DI (n=215)	1.34 units on a scale Standard Deviation 0.75	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 365 HAQ dressing and grooming (n=215)	1.15 units on a scale Standard Deviation 0.93	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 365 HAQ arising (n=215)	0.85 units on a scale Standard Deviation 0.80	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 365 HAQ eating (n=215)	1.26 units on a scale Standard Deviation 1.00	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 365 HAQ walking (n=215)	1.03 units on a scale Standard Deviation 0.86	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 365 HAQ hygiene (n=214)	1.70 units on a scale Standard Deviation 1.06	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 365 HAQ reaching (n=215)	1.73 units on a scale Standard Deviation 1.01	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 365 HAQ gripping (n=216)	1.45 units on a scale Standard Deviation 0.90	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 365 HAQ activities (n=216)	1.52 units on a scale Standard Deviation 1.01	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 449 HAQ-DI (n=116)	1.37 units on a scale Standard Deviation 0.75	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 449 HAQ dressing and grooming (n=116)	1.17 units on a scale Standard Deviation 0.94	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 449 HAQ arising (n=116)	0.84 units on a scale Standard Deviation 0.80	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 449 HAQ eating (n=116)	1.35 units on a scale Standard Deviation 1.03	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 449 HAQ walking (n=116)	1.02 units on a scale Standard Deviation 0.85	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 449 HAQ hygiene (n=117)	1.67 units on a scale Standard Deviation 1.02	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 449 HAQ reaching (n=117)	1.79 units on a scale Standard Deviation 0.96	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 449 HAQ gripping (n=117)	1.50 units on a scale Standard Deviation 0.91	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 449 HAQ activities (n=117)	1.61 units on a scale Standard Deviation 1.01	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 533 HAQ-DI (n=101)	1.33 units on a scale Standard Deviation 0.74	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 533 HAQ dressing and grooming (n=102)	1.15 units on a scale Standard Deviation 0.95	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 533 HAQ arising (n=102)	0.82 units on a scale Standard Deviation 0.80	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 533 HAQ eating (n=102)	1.30 units on a scale Standard Deviation 0.97	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 533 HAQ walking (n=102)	0.98 units on a scale Standard Deviation 0.87	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 533 HAQ hygiene (n=101)	1.57 units on a scale Standard Deviation 1.04	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 533 HAQ reaching (n=101)	1.81 units on a scale Standard Deviation 0.94	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 533 HAQ gripping (n=101)	1.48 units on a scale Standard Deviation 0.97	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 533 HAQ activities (n=101)	1.58 units on a scale Standard Deviation 0.94	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 617 HAQ-DI (n=83)	1.27 units on a scale Standard Deviation 0.68	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 617 HAQ dressing and grooming (n=83)	0.98 units on a scale Standard Deviation 0.88	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 617 HAQ arising (n=83)	0.73 units on a scale Standard Deviation 0.81	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 617 HAQ eating (n=83)	1.33 units on a scale Standard Deviation 0.88	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 617 HAQ walking (n=83)	0.96 units on a scale Standard Deviation 0.76	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 617 HAQ hygiene (n=83)	1.48 units on a scale Standard Deviation 0.95	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 617 HAQ reaching (n=83)	1.70 units on a scale Standard Deviation 0.85	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 617 HAQ gripping (n=83)	1.43 units on a scale Standard Deviation 0.84	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 617 HAQ activities (n=83)	1.57 units on a scale Standard Deviation 0.93	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 729 HAQ-DI (n=63)	1.34 units on a scale Standard Deviation 0.74	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 729 HAQ dressing and grooming (n=63)	1.03 units on a scale Standard Deviation 0.95	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 729 HAQ arising (n=63)	0.81 units on a scale Standard Deviation 0.82	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 729 HAQ eating (n=63)	1.33 units on a scale Standard Deviation 0.97	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 729 HAQ walking (n=63)	1.11 units on a scale Standard Deviation 0.94	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 729 HAQ hygiene (n=63)	1.48 units on a scale Standard Deviation 1.03	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 729 HAQ reaching (n=63)	1.73 units on a scale Standard Deviation 0.81	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 729 HAQ gripping (n=63)	1.57 units on a scale Standard Deviation 0.91	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 729 HAQ activities (n=63)	1.68 units on a scale Standard Deviation 0.96	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 813 HAQ-DI (n=39)	1.38 units on a scale Standard Deviation 0.69	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 813 HAQ dressing and grooming (n=39)	1.18 units on a scale Standard Deviation 0.97	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 813 HAQ arising (n=39)	0.82 units on a scale Standard Deviation 0.79	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 813 HAQ walking (n=39)	1.10 units on a scale Standard Deviation 0.79	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 813 HAQ hygiene (n=39)	1.59 units on a scale Standard Deviation 0.88	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 813 HAQ reaching (n=39)	1.72 units on a scale Standard Deviation 0.76	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 813 HAQ gripping (n=39)	1.36 units on a scale Standard Deviation 0.96	—
Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term Day 813 HAQ activities (n=39)	1.77 units on a scale Standard Deviation 0.93	—

SECONDARY outcome

Timeframe: BL (Day 0), Days 365, 449, 533, 617, 729, 813

HAQ-DI includes 20 questions assessing physical functions in 8 domains:dressing,arising,eating,walking,hygiene,reach,grip and common activities.Domain questions evaluated on 4-point scale: 0=without any difficulty,1=with some difficulty,2=with much difficulty,and 3=unable to do. HAQ-DI=sum of worst scores in each domain ÷ number of domains answered. HAQ-DI minimum=0 (no difficulty), max overall score=3(unable to do). Time-matched mean change from BL= Post-BL value - time-matched BL value. Time-matched BL value=mean BL (Day 0)value for only that cohort with data available at that post-BL visit.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=216 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 HAQ-DI (n=215)	-0.46 units on a scale Standard Error 0.04	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 HAQ dressing and grooming (n=215)	-0.47 units on a scale Standard Error 0.06	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 HAQ arising (n=215)	-0.54 units on a scale Standard Error 0.06	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 HAQ eating (n=215)	-0.58 units on a scale Standard Error 0.06	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 HAQ walking (n=215)	-0.39 units on a scale Standard Error 0.05	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 HAQ hygiene (n=214)	-0.38 units on a scale Standard Error 0.06	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 HAQ reaching (n=215)	-0.38 units on a scale Standard Error 0.05	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 HAQ gripping (n=216)	-0.49 units on a scale Standard Error 0.06	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 HAQ activities (n=216)	-0.47 units on a scale Standard Error 0.06	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 449 HAQ-DI (n=116)	-0.52 units on a scale Standard Error 0.05	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 449 HAQ dressing and grooming (n=116)	-0.59 units on a scale Standard Error 0.08	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 449 HAQ arising (n=116)	-0.60 units on a scale Standard Error 0.07	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 449 HAQ eating (n=116)	-0.66 units on a scale Standard Error 0.08	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 449 HAQ walking (n=116)	-0.52 units on a scale Standard Error 0.07	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 449 HAQ hygiene (n=117)	-0.44 units on a scale Standard Error 0.08	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 449 HAQ reaching (n=117)	-0.44 units on a scale Standard Error 0.07	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 449 HAQ gripping (n=117)	-0.47 units on a scale Standard Error 0.08	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 449 HAQ activities (n=117)	-0.44 units on a scale Standard Error 0.08	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 533 HAQ-DI (n=101)	-0.54 units on a scale Standard Error 0.06	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 533 HAQ dressing and grooming (n=102)	-0.64 units on a scale Standard Error 0.10	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 533 HAQ arising (n=102)	-0.59 units on a scale Standard Error 0.08	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 533 HAQ eating (n=102)	-0.66 units on a scale Standard Error 0.10	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 533 HAQ walking (n=102)	-0.58 units on a scale Standard Error 0.07	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 533 HAQ hygiene (n=101)	-0.50 units on a scale Standard Error 0.09	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 533 HAQ reaching (n=101)	-0.41 units on a scale Standard Error 0.09	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 533 HAQ gripping (n=101)	-0.49 units on a scale Standard Error 0.10	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 533 HAQ activities (n=101)	-0.45 units on a scale Standard Error 0.09	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 617 HAQ-DI (n=83)	-0.59 units on a scale Standard Error 0.07	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 617 HAQ dressing and grooming (n=83)	-0.81 units on a scale Standard Error 0.10	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 617 HAQ arising (n=83)	-0.66 units on a scale Standard Error 0.10	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 617 HAQ eating (n=83)	-0.61 units on a scale Standard Error 0.11	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 617 HAQ walking (n=83)	-0.58 units on a scale Standard Error 0.09	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 617 HAQ hygiene (n=83)	-0.54 units on a scale Standard Error 0.10	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 617 HAQ reaching (n=83)	-0.51 units on a scale Standard Error 0.09	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 617 HAQ gripping (n=83)	-0.51 units on a scale Standard Error 0.10	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 617 HAQ activities (n=83)	-0.47 units on a scale Standard Error 0.10	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 HAQ-DI (n=63)	-0.51 units on a scale Standard Error 0.09	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 HAQ dressing and grooming (n=63)	-0.71 units on a scale Standard Error 0.13	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 HAQ arising (n=63)	-0.59 units on a scale Standard Error 0.12	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 HAQ eating (n=63)	-0.62 units on a scale Standard Error 0.13	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 HAQ walking (n=63)	-0.46 units on a scale Standard Error 0.11	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 HAQ hygiene (n=63)	-0.52 units on a scale Standard Error 0.13	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 HAQ reaching (n=63)	-0.51 units on a scale Standard Error 0.10	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 HAQ gripping (n=63)	-0.33 units on a scale Standard Error 0.10	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 HAQ activities (n=63)	-0.35 units on a scale Standard Error 0.11	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 813 HAQ-DI (n=39)	-0.63 units on a scale Standard Error 0.11	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 813 HAQ dressing and grooming (n=39)	-0.74 units on a scale Standard Error 0.18	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 813 HAQ arising (n=39)	-0.77 units on a scale Standard Error 0.16	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 813 HAQ eating (n=39)	-0.72 units on a scale Standard Error 0.18	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 813 HAQ walking (n=39)	-0.59 units on a scale Standard Error 0.12	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 813 HAQ hygiene (n=39)	-0.51 units on a scale Standard Error 0.17	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 813 HAQ reaching (n=39)	-0.69 units on a scale Standard Error 0.13	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 813 HAQ gripping (n=39)	-0.64 units on a scale Standard Error 0.14	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 813 HAQ activities (n=39)	-0.41 units on a scale Standard Error 0.13	—

SECONDARY outcome

Timeframe: BL, Days 365, 449, 533, 617, 729, 813

Population: All treated participants. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=215 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Number of Participants Achieving Clinically Meaningful HAQ Response Over Time Day 365 (n=215)	124 participants	—
Long-term Period: Number of Participants Achieving Clinically Meaningful HAQ Response Over Time Day 449 (n=116)	69 participants	—
Long-term Period: Number of Participants Achieving Clinically Meaningful HAQ Response Over Time Day 533 (n=101)	62 participants	—
Long-term Period: Number of Participants Achieving Clinically Meaningful HAQ Response Over Time Day 617 (n=83)	53 participants	—
Long-term Period: Number of Participants Achieving Clinically Meaningful HAQ Response Over Time Day 729 (n=63)	38 participants	—
Long-term Period: Number of Participants Achieving Clinically Meaningful HAQ Response Over Time Day 813 (n=39)	26 participants	—

SECONDARY outcome

Timeframe: BL (Day 0)

SF-36 has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health;(2) mental component summary=vitality,social functioning,role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score and 100=best score. Time-matched BL (Day 0) values presented for each post-BL visit represent only that cohort of participants with measurements available at that post-BL visit

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=306 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 PCS (n=297)	28.96 units on a scale Standard Deviation 7.22	—
Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 MCS (n=297)	41.09 units on a scale Standard Deviation 12.90	—
Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 Physical Function Scale Component (n=306)	28.04 units on a scale Standard Deviation 9.88	—
Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 Role-Physical Scale Component (n=300)	31.17 units on a scale Standard Deviation 7.16	—
Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 Bodily Pain Scale Component (n=305)	31.07 units on a scale Standard Deviation 7.39	—
Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 General Health Scale Component (n=308)	35.04 units on a scale Standard Deviation 9.59	—
Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 Vitality Scale Component (n=308)	35.96 units on a scale Standard Deviation 9.11	—
Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 Social Functioning Scale Component (n=308)	34.31 units on a scale Standard Deviation 11.53	—
Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 Role-Emotional Scale Component (n=300)	35.80 units on a scale Standard Deviation 13.80	—
Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 Mental Health Scale Component (n=308)	39.89 units on a scale Standard Deviation 12.86	—
Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 PCS (n=83)	29.76 units on a scale Standard Deviation 6.50	—
Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 MCS (n=83)	36.06 units on a scale Standard Deviation 13.36	—
Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 Physical Function Scale Component (n=89)	26.66 units on a scale Standard Deviation 9.46	—
Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 Role-Physical Scale Component (n=85)	30.87 units on a scale Standard Deviation 6.75	—
Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 Bodily Pain Scale Component (n=86)	29.35 units on a scale Standard Deviation 7.09	—
Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 General Health Scale Component (n=90)	33.23 units on a scale Standard Deviation 9.30	—
Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 Vitality Scale Component (n=90)	36.77 units on a scale Standard Deviation 9.38	—
Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 Social Functioning Scale Component (n=90)	32.59 units on a scale Standard Deviation 12.27	—
Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 Role-Emotional Scale Component (n=85)	30.30 units on a scale Standard Deviation 11.61	—
Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 Mental Health Scale Component (n=89)	33.67 units on a scale Standard Deviation 13.17	—

SECONDARY outcome

Timeframe: Days 365 and 729

Population: All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean post-baseline values reflect changing n-values over time

SF-36 measures health-related quality of life and has 36 questions with 8 subscale scores and 2 summary scores (1)physical component summary=physical functioning,role-physical,bodily pain,and general health; (2)mental component summary=vitality,social functioning,role-emotional,and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0=worst score and 100=best score. Post-BL values presented for each post-BL visit represent only that cohort of participants with measurements available at that post-BL visit.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=306 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term Day 365 PCS (n=297)	35.00 units on a scale Standard Deviation 10.09	—
Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term Day 365 MCS (n=297)	47.15 units on a scale Standard Deviation 12.80	—
Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term Day 365 Physical Function Scale Component (n=306)	33.33 units on a scale Standard Deviation 11.45	—
Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term Day 365 Role-Physical Scale Component (n=300)	37.85 units on a scale Standard Deviation 11.68	—
Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term Day 365 Bodily Pain Scale Component (n=305)	39.78 units on a scale Standard Deviation 9.87	—
Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term Day 365 General Health Scale Component (n=308)	38.58 units on a scale Standard Deviation 10.20	—
Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term Day 365 Vitality Scale Component (n=308)	42.82 units on a scale Standard Deviation 11.27	—
Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term Day 365 Social Functioning Scale Component (n=308)	41.24 units on a scale Standard Deviation 11.81	—
Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term Day 365 Role-Emotional Scale Component (n=300)	42.63 units on a scale Standard Deviation 14.32	—
Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term Day 365 Mental Health Scale Component (n=308)	45.00 units on a scale Standard Deviation 12.82	—
Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term Day 729 PCS (n=83)	36.92 units on a scale Standard Deviation 9.30	—
Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term Day 729 MCS (n=83)	42.06 units on a scale Standard Deviation 12.46	—
Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term Day 729 Physical Function Scale Component (n=89)	33.91 units on a scale Standard Deviation 11.15	—
Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term Day 729 Role-Physical Scale Component (n=85)	37.61 units on a scale Standard Deviation 11.59	—
Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term Day 729 Bodily Pain Scale Component (n=86)	38.89 units on a scale Standard Deviation 10.26	—
Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term Day 729 General Health Scale Component (n=90)	36.99 units on a scale Standard Deviation 9.79	—
Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term Day 729 Vitality Scale Component (n=90)	42.94 units on a scale Standard Deviation 10.45	—
Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term Day 729 Social Functioning Scale Component (n=90)	39.28 units on a scale Standard Deviation 11.66	—
Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term Day 729 Role-Emotional Scale Component (n=85)	37.37 units on a scale Standard Deviation 14.61	—
Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term Day 729 Mental Health Scale Component (n=89)	40.02 units on a scale Standard Deviation 11.80	—

SECONDARY outcome

Timeframe: BL (Day 0), Days 365, 729

SF-36 has 36 questions with 8 subscale scores and 2 summary scores (1)physical component summary=physical functioning,role-physical,bodily pain,and general health; (2)mental component summary=vitality,social functioning,role-emotional,and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0=worst score and 100=best score. Time-matched mean change from BL= Post-BL value - time-matched BL value. Time-matched BL value=mean BL (Day 0)value for only that cohort with data available at that post-baseline visit.

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=306 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 PCS (n=297)	6.04 units on a scale Standard Error 0.55	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 MCS (n=297)	6.06 units on a scale Standard Error 0.63	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 Physical Function Scale Component (n=306)	5.29 units on a scale Standard Error 0.64	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 Role-Physical Scale Component (n=300)	6.69 units on a scale Standard Error 0.68	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 Bodily Pain Scale Component (n=305)	8.70 units on a scale Standard Error 0.56	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 General Health Scale Component (n=308)	3.54 units on a scale Standard Error 0.46	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 Vitality Scale Component (n=308)	6.86 units on a scale Standard Error 0.61	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 Social Functioning Scale Component (n=308)	6.93 units on a scale Standard Error 0.67	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 Role-Emotional Scale Component (n=300)	6.83 units on a scale Standard Error 0.84	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 365 Mental Health Scale Component (n=308)	5.11 units on a scale Standard Error 0.55	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 PCS (n=83)	7.17 units on a scale Standard Error 1.07	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 MCS (n=83)	5.99 units on a scale Standard Error 1.27	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 Physical Function Scale Component (n=89)	7.25 units on a scale Standard Error 1.31	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 Role-Physical Scale Component (n=85)	6.74 units on a scale Standard Error 1.25	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 Bodily Pain Scale Component (n=86)	9.54 units on a scale Standard Error 1.12	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 General Health Scale Component (n=90)	3.76 units on a scale Standard Error 0.99	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 Vitality Scale Component (n=90)	6.16 units on a scale Standard Error 1.09	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 Social Functioning Scale Component (n=90)	6.69 units on a scale Standard Error 1.47	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 Role-Emotional Scale Component (n=85)	7.06 units on a scale Standard Error 1.50	—
Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term Day 729 Mental Health Scale Component (n=89)	6.35 units on a scale Standard Error 1.16	—

SECONDARY outcome

Timeframe: Days 1-813

Population: Treated participants with available serum samples for assay

Outcome measures

Outcome measures
Measure	ST Abatacept (ABA)-Previous User n=25 Participants In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.	ST ABA-Current User In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
LT; Number of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Responses by ELISA Anti-abatacept antibodies	0 participants	—
LT; Number of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Responses by ELISA Anti-CTLA4 antibodies	0 participants	—

Adverse Events

Abatacept (LT)

Serious events: 61 serious events

Other events: 130 other events

Deaths: 0 deaths

Abatacept (ST)

Serious events: 110 serious events

Other events: 372 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Abatacept (LT) n=530 participants at risk	Abatacept (ST) n=1046 participants at risk
Respiratory, thoracic and mediastinal disorders ASTHMA	0.00% 0/530	0.10% 1/1046
Investigations MEDICAL OBSERVATION	0.00% 0/530	0.19% 2/1046
Investigations BLOOD SODIUM DECREASED	0.19% 1/530	0.00% 0/1046
Investigations WHITE BLOOD CELL COUNT DECREASED	0.00% 0/530	0.10% 1/1046
Cardiac disorders ARRHYTHMIA	0.00% 0/530	0.10% 1/1046
Cardiac disorders CARDIOMEGALY	0.00% 0/530	0.10% 1/1046
Cardiac disorders CARDIAC ARREST	0.00% 0/530	0.10% 1/1046
Cardiac disorders ANGINA UNSTABLE	0.00% 0/530	0.10% 1/1046
Cardiac disorders SINOATRIAL BLOCK	0.19% 1/530	0.00% 0/1046
Cardiac disorders ATRIAL FIBRILLATION	0.00% 0/530	0.19% 2/1046
Cardiac disorders MYOCARDIAL INFARCTION	0.19% 1/530	0.29% 3/1046
Cardiac disorders ACUTE CORONARY SYNDROME	0.19% 1/530	0.00% 0/1046
Cardiac disorders CORONARY ARTERY DISEASE	0.00% 0/530	0.10% 1/1046
Cardiac disorders CORONARY ARTERY STENOSIS	0.19% 1/530	0.00% 0/1046
Cardiac disorders AORTIC VALVE INCOMPETENCE	0.00% 0/530	0.10% 1/1046
Cardiac disorders CORONARY ARTERY OCCLUSION	0.00% 0/530	0.10% 1/1046
Cardiac disorders CARDIAC FAILURE CONGESTIVE	0.00% 0/530	0.10% 1/1046
Cardiac disorders ACUTE MYOCARDIAL INFARCTION	0.19% 1/530	0.00% 0/1046
Vascular disorders SHOCK	0.00% 0/530	0.10% 1/1046
Vascular disorders HYPERTENSION	0.19% 1/530	0.10% 1/1046
Vascular disorders AORTIC STENOSIS	0.00% 0/530	0.10% 1/1046
Vascular disorders DEEP VEIN THROMBOSIS	0.00% 0/530	0.10% 1/1046
Psychiatric disorders SUICIDAL BEHAVIOUR	0.00% 0/530	0.10% 1/1046
Hepatobiliary disorders CHOLANGITIS	0.00% 0/530	0.10% 1/1046
Hepatobiliary disorders CHOLELITHIASIS	0.00% 0/530	0.10% 1/1046
Hepatobiliary disorders HEPATOTOXICITY	0.00% 0/530	0.10% 1/1046
Hepatobiliary disorders CHOLECYSTITIS ACUTE	0.00% 0/530	0.10% 1/1046
Hepatobiliary disorders CHOLECYSTITIS CHRONIC	0.00% 0/530	0.10% 1/1046
Hepatobiliary disorders GALLBLADDER ENLARGEMENT	0.00% 0/530	0.10% 1/1046
Immune system disorders ANAPHYLACTIC REACTION	0.00% 0/530	0.10% 1/1046
Nervous system disorders SYNCOPE	0.00% 0/530	0.10% 1/1046
Nervous system disorders HEADACHE	0.00% 0/530	0.10% 1/1046
Nervous system disorders MIGRAINE	0.00% 0/530	0.10% 1/1046
Nervous system disorders SCIATICA	0.19% 1/530	0.00% 0/1046
Nervous system disorders DIZZINESS	0.00% 0/530	0.10% 1/1046
Nervous system disorders CERVICAL ROOT PAIN	0.19% 1/530	0.00% 0/1046
Nervous system disorders LUMBAR RADICULOPATHY	0.00% 0/530	0.10% 1/1046
Nervous system disorders CEREBELLAR INFARCTION	0.00% 0/530	0.10% 1/1046
Nervous system disorders CARPAL TUNNEL SYNDROME	0.00% 0/530	0.19% 2/1046
Nervous system disorders CEREBROVASCULAR ACCIDENT	0.00% 0/530	0.10% 1/1046
Gastrointestinal disorders NAUSEA	0.00% 0/530	0.19% 2/1046
Gastrointestinal disorders COLITIS	0.00% 0/530	0.10% 1/1046
Gastrointestinal disorders MELAENA	0.19% 1/530	0.00% 0/1046
Gastrointestinal disorders RETCHING	0.00% 0/530	0.10% 1/1046
Gastrointestinal disorders VOMITING	0.19% 1/530	0.19% 2/1046
Gastrointestinal disorders DIARRHOEA	0.19% 1/530	0.00% 0/1046
Gastrointestinal disorders GASTRITIS	0.19% 1/530	0.10% 1/1046
Gastrointestinal disorders STOMATITIS	0.19% 1/530	0.00% 0/1046
Gastrointestinal disorders PANCREATITIS	0.19% 1/530	0.00% 0/1046
Gastrointestinal disorders GASTRIC ULCER	0.00% 0/530	0.10% 1/1046
Gastrointestinal disorders ABDOMINAL PAIN	0.19% 1/530	0.10% 1/1046
Gastrointestinal disorders MOUTH ULCERATION	0.00% 0/530	0.10% 1/1046
Gastrointestinal disorders UMBILICAL HERNIA	0.19% 1/530	0.00% 0/1046
Gastrointestinal disorders COLITIS ISCHAEMIC	0.00% 0/530	0.19% 2/1046
Gastrointestinal disorders RECTAL HAEMORRHAGE	0.00% 0/530	0.10% 1/1046
Gastrointestinal disorders ABDOMINAL PAIN UPPER	0.00% 0/530	0.10% 1/1046
Gastrointestinal disorders PROCTITIS ULCERATIVE	0.19% 1/530	0.00% 0/1046
Gastrointestinal disorders OESOPHAGEAL OBSTRUCTION	0.00% 0/530	0.10% 1/1046
Gastrointestinal disorders GASTROINTESTINAL HAEMORRHAGE	0.00% 0/530	0.10% 1/1046
Ear and labyrinth disorders DEAFNESS	0.00% 0/530	0.10% 1/1046
Infections and infestations PNEUMONIA	0.38% 2/530	0.38% 4/1046
Infections and infestations UROSEPSIS	0.00% 0/530	0.10% 1/1046
Infections and infestations BRONCHITIS	0.00% 0/530	0.29% 3/1046
Infections and infestations BACTERAEMIA	0.19% 1/530	0.00% 0/1046
Infections and infestations PHARYNGITIS	0.19% 1/530	0.00% 0/1046
Infections and infestations APPENDICITIS	0.19% 1/530	0.00% 0/1046
Infections and infestations SEPTIC SHOCK	0.00% 0/530	0.10% 1/1046
Infections and infestations HERPES ZOSTER	0.19% 1/530	0.00% 0/1046
Infections and infestations DIVERTICULITIS	0.00% 0/530	0.10% 1/1046
Infections and infestations PYELONEPHRITIS	0.19% 1/530	0.10% 1/1046
Infections and infestations ACUTE SINUSITIS	0.00% 0/530	0.10% 1/1046
Infections and infestations GASTROENTERITIS	0.57% 3/530	0.10% 1/1046
Infections and infestations LOBAR PNEUMONIA	0.00% 0/530	0.19% 2/1046
Infections and infestations TOOTH INFECTION	0.00% 0/530	0.10% 1/1046
Infections and infestations VIRAL INFECTION	0.19% 1/530	0.00% 0/1046
Infections and infestations TRACHEOBRONCHITIS	0.00% 0/530	0.10% 1/1046
Infections and infestations ABSCESS INTESTINAL	0.00% 0/530	0.10% 1/1046
Infections and infestations ESCHERICHIA SEPSIS	0.00% 0/530	0.10% 1/1046
Infections and infestations ARTHRITIS BACTERIAL	0.00% 0/530	0.10% 1/1046
Infections and infestations ARTHRITIS INFECTIVE	0.00% 0/530	0.10% 1/1046
Infections and infestations HAEMOPHILUS INFECTION	0.00% 0/530	0.10% 1/1046
Infections and infestations PNEUMONIA PNEUMOCOCCAL	0.00% 0/530	0.10% 1/1046
Infections and infestations URINARY TRACT INFECTION	0.19% 1/530	0.10% 1/1046
Infections and infestations STAPHYLOCOCCAL INFECTION	0.19% 1/530	0.00% 0/1046
Infections and infestations GASTROENTERITIS NOROVIRUS	0.00% 0/530	0.10% 1/1046
Infections and infestations GASTROENTERITIS SALMONELLA	0.00% 0/530	0.10% 1/1046
Infections and infestations POSTOPERATIVE WOUND INFECTION	0.00% 0/530	0.10% 1/1046
Infections and infestations UPPER RESPIRATORY TRACT INFECTION	0.19% 1/530	0.10% 1/1046
Renal and urinary disorders NEPHROLITHIASIS	0.19% 1/530	0.10% 1/1046
Renal and urinary disorders RENAL FAILURE ACUTE	0.00% 0/530	0.19% 2/1046
Renal and urinary disorders STRESS URINARY INCONTINENCE	0.19% 1/530	0.00% 0/1046
Renal and urinary disorders MESANGIOPROLIFERATIVE GLOMERULONEPHRITIS	0.19% 1/530	0.00% 0/1046
Metabolism and nutrition disorders OBESITY	0.19% 1/530	0.00% 0/1046
Metabolism and nutrition disorders DEHYDRATION	0.19% 1/530	0.00% 0/1046
Metabolism and nutrition disorders HYPOKALAEMIA	0.00% 0/530	0.19% 2/1046
Metabolism and nutrition disorders DIABETIC KETOACIDOSIS	0.00% 0/530	0.10% 1/1046
Blood and lymphatic system disorders ANAEMIA	0.19% 1/530	0.19% 2/1046
Blood and lymphatic system disorders COAGULOPATHY	0.00% 0/530	0.10% 1/1046
Blood and lymphatic system disorders MICROCYTIC ANAEMIA	0.19% 1/530	0.00% 0/1046
Skin and subcutaneous tissue disorders URTICARIA	0.19% 1/530	0.00% 0/1046
Skin and subcutaneous tissue disorders ANGIOEDEMA	0.00% 0/530	0.10% 1/1046
Reproductive system and breast disorders MENORRHAGIA	0.00% 0/530	0.10% 1/1046
Reproductive system and breast disorders OVARIAN CYST	0.00% 0/530	0.10% 1/1046
Reproductive system and breast disorders POLYMENORRHOEA	0.00% 0/530	0.10% 1/1046
Reproductive system and breast disorders UTERINE PROLAPSE	0.19% 1/530	0.10% 1/1046
Injury, poisoning and procedural complications FALL	0.19% 1/530	0.00% 0/1046
Injury, poisoning and procedural complications WOUND	0.19% 1/530	0.00% 0/1046
Injury, poisoning and procedural complications OVERDOSE	0.00% 0/530	0.10% 1/1046
Injury, poisoning and procedural complications ANKLE FRACTURE	0.00% 0/530	0.10% 1/1046
Injury, poisoning and procedural complications FEMUR FRACTURE	0.00% 0/530	0.10% 1/1046
Injury, poisoning and procedural complications FIBULA FRACTURE	0.19% 1/530	0.00% 0/1046
Injury, poisoning and procedural complications RADIUS FRACTURE	0.19% 1/530	0.00% 0/1046
Injury, poisoning and procedural complications UPPER LIMB FRACTURE	0.19% 1/530	0.00% 0/1046
Injury, poisoning and procedural complications FEMORAL NECK FRACTURE	0.00% 0/530	0.10% 1/1046
Injury, poisoning and procedural complications ROAD TRAFFIC ACCIDENT	0.19% 1/530	0.00% 0/1046
Injury, poisoning and procedural complications MEDICAL DEVICE COMPLICATION	0.19% 1/530	0.10% 1/1046
Musculoskeletal and connective tissue disorders BURSITIS	0.19% 1/530	0.00% 0/1046
Musculoskeletal and connective tissue disorders ARTHRITIS	0.00% 0/530	0.19% 2/1046
Musculoskeletal and connective tissue disorders BACK PAIN	0.19% 1/530	0.19% 2/1046
Musculoskeletal and connective tissue disorders ARTHRALGIA	0.38% 2/530	0.19% 2/1046
Musculoskeletal and connective tissue disorders METATARSALGIA	0.19% 1/530	0.00% 0/1046
Musculoskeletal and connective tissue disorders OSTEONECROSIS	0.19% 1/530	0.00% 0/1046
Musculoskeletal and connective tissue disorders OSTEOARTHRITIS	0.94% 5/530	0.48% 5/1046
Musculoskeletal and connective tissue disorders COSTOCHONDRITIS	0.00% 0/530	0.10% 1/1046
Musculoskeletal and connective tissue disorders TENDON DISORDER	0.19% 1/530	0.00% 0/1046
Musculoskeletal and connective tissue disorders MUSCULOSKELETAL PAIN	0.00% 0/530	0.10% 1/1046
Musculoskeletal and connective tissue disorders RHEUMATOID ARTHRITIS	2.8% 15/530	1.6% 17/1046
Musculoskeletal and connective tissue disorders ROTATOR CUFF SYNDROME	0.00% 0/530	0.10% 1/1046
Musculoskeletal and connective tissue disorders SPINAL OSTEOARTHRITIS	0.00% 0/530	0.10% 1/1046
Musculoskeletal and connective tissue disorders SPINAL COLUMN STENOSIS	0.19% 1/530	0.10% 1/1046
Musculoskeletal and connective tissue disorders INTERVERTEBRAL DISC PROTRUSION	0.19% 1/530	0.29% 3/1046
Musculoskeletal and connective tissue disorders INTERVERTEBRAL DISC DEGENERATION	0.00% 0/530	0.10% 1/1046
Respiratory, thoracic and mediastinal disorders DYSPNOEA	0.19% 1/530	0.00% 0/1046
Respiratory, thoracic and mediastinal disorders NASAL POLYPS	0.00% 0/530	0.10% 1/1046
Respiratory, thoracic and mediastinal disorders PNEUMOTHORAX	0.00% 0/530	0.10% 1/1046
Respiratory, thoracic and mediastinal disorders LUNG DISORDER	0.00% 0/530	0.10% 1/1046
Respiratory, thoracic and mediastinal disorders PULMONARY BULLA	0.00% 0/530	0.10% 1/1046
Respiratory, thoracic and mediastinal disorders PLEURAL EFFUSION	0.00% 0/530	0.10% 1/1046
Respiratory, thoracic and mediastinal disorders PULMONARY EMBOLISM	0.38% 2/530	0.00% 0/1046
Respiratory, thoracic and mediastinal disorders RESPIRATORY FAILURE	0.00% 0/530	0.10% 1/1046
Respiratory, thoracic and mediastinal disorders PULMONARY THROMBOSIS	0.00% 0/530	0.10% 1/1046
Respiratory, thoracic and mediastinal disorders CHRONIC OBSTRUCTIVE PULMONARY DISEASE	0.19% 1/530	0.00% 0/1046
General disorders ULCER	0.19% 1/530	0.00% 0/1046
General disorders PYREXIA	0.19% 1/530	0.00% 0/1046
General disorders ASTHENIA	0.19% 1/530	0.00% 0/1046
General disorders CHEST PAIN	0.57% 3/530	0.38% 4/1046
General disorders CHEST DISCOMFORT	0.00% 0/530	0.19% 2/1046
General disorders IMPAIRED HEALING	0.00% 0/530	0.10% 1/1046
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LYMPHOMA	0.19% 1/530	0.00% 0/1046
Neoplasms benign, malignant and unspecified (incl cysts and polyps) HAEMANGIOMA	0.00% 0/530	0.10% 1/1046
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BREAST CANCER	0.00% 0/530	0.19% 2/1046
Neoplasms benign, malignant and unspecified (incl cysts and polyps) UTERINE CANCER	0.00% 0/530	0.10% 1/1046
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LUNG ADENOCARCINOMA	0.00% 0/530	0.10% 1/1046
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BASAL CELL CARCINOMA	0.19% 1/530	0.29% 3/1046
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BLADDER CANCER RECURRENT	0.19% 1/530	0.00% 0/1046

Other adverse events

Other adverse events
Measure	Abatacept (LT) n=530 participants at risk	Abatacept (ST) n=1046 participants at risk
Nervous system disorders HEADACHE	4.7% 25/530	9.8% 102/1046
Gastrointestinal disorders NAUSEA	4.9% 26/530	8.6% 90/1046
Gastrointestinal disorders DIARRHOEA	4.5% 24/530	5.5% 58/1046
Infections and infestations SINUSITIS	4.5% 24/530	6.0% 63/1046
Infections and infestations BRONCHITIS	5.7% 30/530	4.7% 49/1046
Infections and infestations NASOPHARYNGITIS	6.4% 34/530	3.1% 32/1046
Infections and infestations UPPER RESPIRATORY TRACT INFECTION	4.7% 25/530	7.9% 83/1046

Additional Information

BMS Study Director

Bristol-Myers Squibb

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.
Publication restrictions are in place

Restriction type: OTHER